cox proportional hazard
young woman ; family

case-control study
EH
patients
Clinical
benefits
HF
complications
Cell
doxorubicin
transfusions


molecular mechanism
dXA
devices in heart failure
FM
Liver disease
adverse events
HF ; PNA

Renal artery stenosis
cohort study
heart transplant recipients
hospital mortality
production ; EC
tertiary referral centre


heart failure ; Latin America
cohort
multivariate
HF
mortality


trial
doctors


Heart rate
Nutrition in heart failure

heart failure
surgery
Cross-sec
INTERventions
unilateral
Heart failure

alternative
clin


Jehovah


dodson

CHF

intermediate frail
Dynamic ; competitive
autonomic balance
LV fibrosis
HFpEF


Heart failure ; cognitive impairment ; mortality
cardiology ; university hospital
median
HF
heart failure
inpatient medical conditions
frailty ; HF
CO ; mixed linear models
cardiac transplantation
cognitive function ; quality
Heart rate variability
taxonomy
descriptive research
Sham


policy

prognostic
Heart failure
rates ; CHF
air pollution ; heart failure

cardiovascular disease
HF ; MI
extracorporeal
Heart failure
hemostasis

ischemic conditioning ; heart failure
Heart failure ; bisphosphonates
right heart failure ; pulmonary hypertension
caspase ; heart failure
diuretic ; heart failure



hypertension
HF
Heart rate ; arterial

Chronic HF
Cardiac amyloidosis
Robot-assisted training ; heart failure
Literature
MR ; MS
hpEF
ejection fraction ; sex ; bNP
Pigs ; antiarrhythmic medication
beta blockade
CHF patients
surgical ; circulatory arrest
functional capacity ; quality
systolic dysfunction
cronbach
trial
frailty in heart failure
Median age

implanted monitoring devices

patient safety
HR modulates Ea

RAS ; atherosclerosis

microRNAs in heart failure ; disease management
cox regression
PSSS
management ; heart failure ; ejection fraction
Cardiology ; inhibition halts heart failure
heart failure hospitalization ; cardiovascular death
Mitral stenosis reversed ; medical treatment ; heart failure
vasopressin ; congestive heart
Trastuzumab-related cardiotoxicity ; breast cancer
Medication
physician volume ; hospital volume
mortality
pde2 ; HF
Nights spent in hospital
Heart failure ; public health
postoperative normalization ; albumin
aortic pressure curve
physician continuity
Arrhythmia-related costs
implants ; heart failure ;HF
Cardiac
spironolactone ; systolic heart failure
molecular scaffolds ; heart pathologie
MS ; degenerative MR
implantologie ; chronic heart failure ; bisoprolol
Heart failure ;HF ; mortality
cox proportional hazards
Tolvaptan ; vasopressin
réseau meta-analysis

propensity
patients
black patients

metric choice ; readmission metrics
ET ; CHF
readmission metric
HF


Median
heart failure
mortality
cardiac ; inflammatory biomarkers
HF ; cardiovascular hospitalization
hgb ; baseline HRQoL
ejection fraction
biomarkers ; chronic heart failure
survival
cox proportional hazards models
kidney injury
multiorgan failure ; sepsis
psychometric testing ; Self-Care of Heart Failure Index
Nordic walking
cox proportional hazard analyses

Pharmacological treatment ; acute heart failure
MS
Hemodynamic ; failing Fontan
Coronary angiography
dialysis ; implantation
off-pump sternal sparing approach ; HeartMate
VO2max


HR
ESRD
mAIN oUTCOME MEasURE
biomarkers


heart failure
healthcare programmes

abnormal cardiac
trials

interventions
risk
Heart failure ; ventricular ejection fraction
HR variability ; sudden

chronic kidney disease ;CKd
progressive disease ; hypertension ; kidney failure
hospital ; heart failure
muscle abnormalities ; exercise capacity ; Fontan circulation
Physician volume
systolic HF
mAIN oUTCOME ; readmissions
prognosis
venting hemodynamics
indices
implantation
patient satisfaction
gross income ; health
aac ; cardiac hypertrophy
AHA ; ESC

HF

HF
patients ; heart failure
acute heart failure
toxicity ; systemic blood pressure
circulation
cPGs

therapy


ms
endothelial function
nursing terminologies
HF ; chromatin hyperacetylation

care management ; telehealth ; medicare

public reporting
sinus rhythm ; AF
heart failure ; cardiac rehabilitation
spironolactone ; heart failure
Myocardial infarction ; adult male Wistar rats
patients ; HF
anemia treatment ; heart disease
race ; exercise
Rhythm- ; rate-control
ingenuity pathway
lVAD AI
implant
acute heart failure

QRs duration




deficit index
grLS ; CV events
ms

anaerobic threshold ; heart failure
renin-angiotensin-aldosterone system inhibitors ; heart failure
CHF ; unilateral renal DNx ; cardiac autonomic balance
Mitral regurgitation
feasibility
Heart block ; pulmonary artery snared ; biVP
inflammation ; metabolism ; heart disease
cause ; systolic HF
diuretic ; HF
cardiovascular events
bioinformatic analysis ; microarray
af patients ; echocardiographic examination
MS
congenital heart lesions

PVf ; PB
économique savings
Nurses ; patients
BB therapy
MS ; HF ; surgical indication
ICU mortality
Cardiac function ; pressure-volume conductance catheter system
cRT ; dialysis-dependent patients
beta-blockers
CHF

HF
cardiomyopathy ; male sex ; mortality
cardiac sodium current ; systolic human heart failure
diastolic dysfunction ; peripheral artery disease
immunohistochemistry ; electron microscopy
angiotensin receptor neprilysin inhibitor ; heart failure
idiopathic dilated cardiomyopathy
hypertensive LV dysfunction ; MR ; MS
hypoalbuminemia
cd HF
MS
Protective effects ; ed ; endothelial function
ff ; FM ; figure
coronary disease ; heart failure
safety end point
dialysis
implantive ; maladaptive cardiac remodelling
heart transplant
precipitating factor ; hff
hHF ; dp-4 inhibitors ; drugs
branch block electrical activation
Southeastern Minnesota ; HF
Frailty ; risk ; HF
proteome ; HDL particles ; shotgun LC-MS
multihospital study ; heart failure guidelines
proteins ; TAC
Cardiac cachexia ;CC
rehospitalization
social support ; figure

cRF
Mediterranean ; DASh
diabetes ; EO-CFUs
risk ; hospitalization ; heart failure clinic
Cardiac-resynchronization therapy ; heart failure
hospital readmission reduction ; congestive heart failure
hf ; HFpEF
physician continuity
nitroxyl ; hno ; acute treatment of heart failure
change ; lVET ; follow-up
odds ratios
blacks
pharmaceutically


trastuzumab-related CHF
implants
VO2
hospitals
financiers
patient safety
remodelling ; HF ; haemodynamic ; neuronal stressors
Heart failure ; rheumatoid arthritis ; TNF antagonist
mortality ; HF hospital admissions ; transplant ; ventricular assist device
Coronary artery disease ;CAD ; systolic heart failure ;HF
preoperative hypoalbuminemia
holosystolic murmur
psoriasis ; atherosclerosis ; incident cardiovascular events
CV death ; stroke ; heart failure
Renal artery stenosis ;RAS ; peripheral arterial disease
resistin ; heart failure
subclinical atherosclerosis
Wilcoxon
incidence ; ESRD ; HF
ventricular assist device ; ventricular support
baseline ECGs
ventricular function ; body composition
deficit index ; biological phenotype
intolerance ; chronic heart failure
heart transplantation ; ventricular assist device
ECCT ; advanced heart failure therapy
atrial fibrillation ;AF ; heart failure
Fat ; cachexia ; ventricle ; heart failure
AVd ; VVD ; free wall RS
preoperative clinical
renal denervation ; autonomic balance ; conscious rabbits ; heart failure
regulatory subunit ;RI
pediatrc heart failure ;HF ; morbidity
heart failure ; medication
heart failure ; ejection fraction
cPET guiding exercise rehabilitation ; CHF
eplerenone
ECCT ; cardiac transplant
VEGF inhibition ; b ; cardiac ; remodeling
Heart failure ;HF ; cardiovascular hospitalization
technique ; malfunctioning HeartMate ; lVADs
transfusion

discharge
β-blocker ;BB ; sST2
bromodomain proteins
miRNAs
medications
mortality ; iCD-HF
septal defect
MLHF
coronary heart disease ; stroke
mortality
bt ; DT
heart failure

incident HF
biomarkers ; HF
hypotension

économique
figure ; CAD
renal dysfunction ; long-term survival
implantation
Cardiac hypertrophy ; energy metabolism
NP assessment ; ED
trastuzumab

Renal DNx ; circulating plasma ; CHF-INv rabbits
Heart failure disease management ; medical resource
hCT germline DNA ; genotype
HDL-bound malondialdehyde ; HDL-induced ; EC
HF

anemia in adults ; heart disease

survival
hospitals

heart failure
Myxomas ; pulmonary arterial vasculature
Orthotopic heart transplantation ; oHT ; end-stage heart failure
Right atrial myxoma ; pulmonary embolism ; right heart failure
Nfat ; mir-25 ; transcription factor ; Hand2 in heart failure
resistin ; decline ; ejection fraction
Framingham Heart Study ; HF ; EF
coronary artery disease ;CAD
diuretics
HF
rhythm control therapy ; cardiovascular complications
Cardiac ; Mammalian enabled ; mena ; heart failure
lVAS
canine model ; chronic heart failure ; tachycardia
dysfunction ; pump failure ; driveline injury
cPCs ; functional capacity ; VO2
therapies
Nicorandil ; doxorubicin

EH
ischemic ; inflammatory abdominal
aCP ; clinical practice guidelines
MedLine ; EMBASE ; cINAHL
ED visits ; intubations ; congestive heart failure
aCR ; CMS
HF
hf ; saxagliptin ; sitagliptin
Frailty ; risk ; heart failure ; aging
caspase ; mlocardium
heart

implantation
électronique databases ; World health Organization ; HF
therapy
degs ; osprey
clinical change

Medicare ; post-acute care transfer policy
QRs
ED visits
deficit index
Diet ; nuts ; whole grain intake
groupes validity ; internal consistency ; test-retest
iron
RAS ; β-blocker uptitration ; HFpEF
Gastrointestinal bleeding ; ventricular assist devices ; cardiac nurse
QT intervals ; SD
bottleneck stent ; chronic myocardial ischemia ; heart failure ; pigs
hospital discharge in patients ; heart failure
ventricular contractile reserve ; pulmonary hypertension
implanting
Soluble ST2 in ambulatory patients ; heart failure
LV filling pressure ; HF
Titin hypophosphorylation ; myocardial DD
atrial fibrillation ; pacemaker
implantation ; myocardial fibrosis
medical management ; heart failure ; Canadian Cardiovascular Society guidelines
psychosocial factors ; exercise ; heart failure ;HF
emergency cardiac catheterization
pump exchanges ; pump ; thrombosis ; hemolysis
implantions
HRQoL
noc
cardiac resynchronization therapy ; dialysis-dependent patients
active treatment
inpatient records ; HF
aRIC HF
skeletal muscle mass ; VO2
ventricular-arterial coupling ; SV
pneumonia
autonomic nervous system activity ; QTV
diastolic failure ; cardiomyopathic restriction
therapy
mortality ; iCD-HF
figure ; pka
body mass index ; cRF ; treadmill
AF-free probability ; catheter ablation ; maintenance ; sinus rhythm
cardiac transplants
ethics Rounds





renal DNx ; cardiac autonomic balance ; CHF ; sympathetic tone
heart rate reduction ; ivabradine unloads ; left ventricle ; heart failure
anemia ; heart disease ; clinical practice guideline
biomarkers ; neurohormonal stimulation ; inflammation ; endothelial dysfunction
end-stage renal disease ; outpatients ; systolic heart failure
Heart Failure ; Pathophysiology ; Medical Treatment Guidelines ; Nursing Management
RVPO ; BiVP ; CO ; RS synchrony ; CS
parasympathetic neurotransmission ; acetylcholinesterase inhibition
echocardiographic ; reverse remodeling ; cardiac resynchronization therapy
neurohormonal abnormalities ; pathophysiology ; congestive heart failure ;CHf
implant ; chronic heart failure ; lipoprotein functional properties
cardiovascular death ; HF hospitalization ; btes
acute autonomic nervous system modulation ; QTV
resistin ; acute anthracycline-induced cardiotoxicity
Myocardial ; HF
hospitalisations ; readmissions
heart rate ; aortic blood flow ; doxorubicin
BAT ; sympathetic outflow ; parasympa
congestive heart failure ;CHf
chromatin subproteome ; mouse heart
pulmonary artery ; right pulmonary artery
resistin levels ; anthracycline-treated breast cancer ; cardiotoxicity
cPCs ; diabetes
Mediterranean ; DASh diet scores ; mortality ; heart failure ; Womens Health Initiative
LVEF ; long-term mortality
dobutamine ; furosemide ; oxygen
miRNAs ; heart failure
Jehovah's Witness ; sickle cell disease
mRI scanner
health Buddy Program ; ED
therapeutic
l-type ca2+ currents ; rad ; congestive heart failure
physician continuity
cardiac stress
PSSS ; social support ; btes
therapeutic options
Frailty ; elderly
muscle-wasting syndrome ; acquired heart
Health Buddy Program ; content-driven telehealth system ; care management
bisoprolol ; mortality
ED ; CHF ; intubation rates
Medicare fee-for-service beneficiaries
Student t test ; confidence intervals ;CIs
myocardial diastolic dysfunction ;DD
systolic ; diastolic mitral leaflet motions
doppler echocardiography ; pulmonary hypertension
circulating progenitor cells ; heart failure
LV strain
septal wall CS ; avd ; free wall CS ; VVD
acute RV failure ; left ventricular dysfunction
biventricular pacing ; left heart twist ; strain ; porcine model of right heart failure
implantation ; circulatory assist device
morbidity ; mortality
cPCs ; functional capacity ; heart failure ;HF
ctnt ; NT-probNP ; HF
inhibition ; protein kinase ; soluble guanylate cyclase
HR reduction ; beta blockers ; exercise capacity
mg myocardial washout
cohort study
cardiopulmonary exercise variables
inhospital mortality ; bNP
radiological signs
coût ; heart failure ;HF
ventricle ; RV ; cardiac
Mortality
RV dysfunction
transcatheter
beta blockers
p ; refractory ; end-stage congestive heart failure ;CHf
HF ; valve plasty ; MS
pressure ulcers ; surgical
median baseline ST2 level

therapeutic functions
Nursing-sensitive outcome change scores ; hospitalized older adults ; heart failure
black race ; mortality
insurance status ; comorbidities
Human resistin ; chemotherapy-induced heart failure ; humanized male mice ; breast cancer
social support ; barriers

chelation regimens ; heart iron
consultation ; abdominal
Timed up ; Go test ; chronic organ failure
complication
fréquence
mortality
futility
ejection fraction ; cardiac resynchronization therapy ; mild heart failure
aortic valve insufficiency ; ventricular assist device implantation
ventricular ejection ; acute heart failure ; precapillary pulmonary hypertension
pacing-induced dilated cardiomyopathy
right atrium mass ; prolapse ; tricuspid valve ; stenotic physiology
California office of Statewide Health Planning ; Development Patient Discharge
cardiac catheterization ; thrombotic obstruction ; right coronary artery
echocardiographic ; invasive hemodynamic
hFPEF ; dietary sodium restriction ; ventricular ; vascular stiffness
mt
chronic heart failure ;CHf ; sympathetic tone ; autonomic imbalance
CHF atrial explants ; c-Kit ; cells
magnetically Levitated left ventricular Assist System ; Treating Advanced HF
Fontan failure ; ventricular
Heart failure ; mortality ; Western society
HF
membrane oxygenation ; bridge to recovery ; infarction-related refractory right heart failure
protein levels ; Western blot ; DNA fragmentation ; TUnel
cardiac filling pressures
implantable cardioverter-defibrillator deactivation
Chinese herbal medicine ; dilated cardiomyopathy ; heart failure
trastuzumab
electromechanical delay ; dyssynchronous heart failure
cardiac Mena deletion ; cardiac dysfunction ; hypertrophy
économique impact ; af ; heart failure

bundle-branch block ;LBBB
BETs ; mouse TAC ; human HF
patients ; systolic function
HDL-induced NO production ; flow-mediated dilatation
cPG ; HF
cox regression ; cardiovascular events ; psoriasis
heart failure ; altered protein kinase
NT-probNP
dopamine
temps-varying Seattle Heart Failure
HF
patients ; aHF
chemical instability ; cogeneration ; nitrite
neurological ; cardiovascular
MADit-cRT
consultations
transfusion ; mortality
Czech Republic
cardiac nurses
study closure
UM/VA/VA-RT
risk ; heart failure
coût-effective
preoperative serum albumin ; implantation
Western blots ; monoclonal antibodies ; Ser83 phosphorylation
HRQoL
interleukin receptor family ; ST2 ; beta-blocker therapy ; chronic heart failure
ventricular assist device ; extracorporeal membrane oxygenation
echocardiography
exercise intolerance in heart failure
MS ; ring annuloplasty ; ischemic MR ; LV dilatation
Heart Association
pathophysiology ; HF
vasopressin receptor antagonist ; tolvaptan ; Japanese heart failure
Paco2 cerebral blood flow ; carotid bodies
cox models
ED physicians ; suburban hospitals
TM interventions ; STS
psoriasis patients ; smoked ; diastolic blood pressure ; body
ECmo group ; VAD ; ECmo+VAD
inotropic effect ; beta blockers
anticoagulation ; therapy ; underlying heart disease
mortality ; morbidity ; cancers
energy metabolism ; heart failure
NT-probNP ; circulation ; HF
HR reduction ; ivabradine ; TAC
PAD ; ankle-brachial index
MS ; LV dilatation
mechanical cardiac support ; renal
renal dysfunction
implanted
ventricular dilatation
anemia ; patients ; heart disease
CF lVAD patients ; AI ; heart failure
rhythm-control
patients ; heart failure
HF epidemiology ; health service ; HF
Functional MS
hemoglobin levels
ventricular assist devices ; device therapies
Heart failure ;HF ; debilitating chronic disease
heart failure ;HF
serum factors
cfa
PB ; HF

computing readmissions ; hospital rankings
iCD

HF
pro-adrenomedullin ;MR-proADm ; ff
Cardiorespiratory fitness ; body mass index ; heart failure mortality
bNP ; NT-proBNP

adenylyl cyclase ; g-protein coupling
heart failure ;HF ; ventricular ejection fraction ;HFpEF
Circulating fragments ; natriuretic peptides ; plasma ; heart failure
ejection fraction ;EF ; collateral growth ; myocardial perfusion
Heart failure ;HF ; sympathetic activity ; parasympathetic control ; heart
atrial fibrillation ; congestive heart failure
cardiovascular risk ; diabetes mellitus ; hypertension
ATP demand ; XO-mediated ROS ; mitochondrial respiration
implantable cardiac defibrillator
implantation ; long-term ventricular assist device
systolic HF ; unclear etiology ; coronary angiography
HF ; cardiac murmurs ; hg
Exercise intolerance ; chronic hff ; qOL
isoproterenol ; cXL-1020 ; myocytes
Pyridostigmine ; myocyte diameter ; collagen density ; surviving left ventricle
implantation instability ; heart failure ; ventricular tachycardia
cardiac angiogenesis ; in vivo coronary perfusion ; cardiac fibrosis
biventricular dysfunction ; implanted HeartMate
HF ; spontaneous VT ; beat-to-beat QT
social mandate
signaling pathways ; pressure-overload-induced heart failure
tug test ; patients ; advanced COPd ; CHF ; cRF
hemodynamically unstable
ECmo group ; eGFR
sonographic ; histological ; functional abnormalities
aCS procedures ; MT ; VAD
HR ; tNF antagonists ; nbDMARD
population-based Rotterdam Study ; psoriasis
structure ; SCHFI
energy substrate metabolism
CVd ; psoriasis
diabetes mellitus ; cardiovascular
patients ; CAD
hospital ; cardiac specialty hospital
haemodynamic ; pulmonary
structure ; medical records
diagnostic ; prediction rule
HF-related cachexia ; RV ; body composition
cognitive impairment ; mortality
hospital ; rehospitalization
hospital mortality
acute HF
administration ; trastuzumab ; CHF
long-term survival
hospitals
biomarker-guided clinical
sudden cardiac death
mechanical cardiac support ; renal function ; end-stage heart failure
functional mitral stenosis ; ring annuloplasty ; ischemic mitral regurgitation
heart transplantations ;LV assist device implantations
ventricular longitudinal systolic strain ; cardiovascular events ; atrial fibrillation
mouse HF ; transition ; compensated LV hypertrophy ; HF
anticoagulants ; antiplatelet drugs ; heart failure ; atrial fibrillation
natriuretic peptide ; biomarkers
sympathetic ; parasympathetic
bNP ; PAD ; bNP ; HF
Spironolactone ; hyperkalemia
chronic myocardial ischemia ; heart failure
EH ; renal impairment
HFpEF
race ; outcomes
parasympathetic ; therapeutic alternative
Heart failure ;HF
jugular venous pressure ; peripheral oedema
HF ; ms ; mva
hgb
surgical revascularization
technique ; redo sternotomy ; cardiopulmonary
clinical prediction rule ; CAD ; cause ; systolic HF
Morpholino-based knockdown ; nucleolin ; protein expression
MS ; HF
cardiovascular conditions
réseau ; Cytoscape ; functional enrichment
hypertension ; diabetes ; ischemic etiology ; socioeconomic status
NT-proBNP testing ; long-term survival ; ED ; acute heart failure
health insurance ; health system ; ues ; Food and Drug Administration
lVAD ; biventricular
Fontan circulation ; sVR index ; cardiac index
Fontan circulation ; skeletal muscle
hereditary ; congenital abnormalities ; heart
mineralocorticoid receptor antagonists
lVAD
HeartMate II lVAD
practice
Bisphosphonate ; heart failure
right heart circulation
Raf-MEK1/2-ERk1/2 signalling pathway
MI ; HF
HF-induced remodeling ; EMd prolongation
coût ; survival
sustainability ; commissioning ; hospital-based programmes
maladaptive molecular
patient safety initiatives
heart failure ; preserved ejection fraction ; clinical doppler echocardiography
Xanthine oxidase inhibition ; ventricular systolic ; diastolic ; cardiac volume
spironolactone ; systolic heart failure
nonselective ; beta-blockers ; cardiac sympathetic activity ; hemostasis
myocardial ischemic events ; cardiac resynchronization
β-Blockade ; cardiac angiogenesis ; heart failure ; VEGF signaling pathway
parasympathetic tone ; pyridostigmine ; ventricular dysfunction ; heart failure
HF ; preserved ejection fraction ;HFpEF ; hypertension
heart failure ;HF ; Heart Failure Adherence ; retention Trial ;HART
HFpEF
Myocardial infarction ; left anterior descending coronary artery occlusion
NYha functional class ; quality-of-life score
aortic valve surgery ; new-onset ; lVAD
immunodetection ; NT-proBNP
unloading of the heart ; HR reduction
Nordic walking ; cardiac rehabilitation
oxidative stress ; GTPase Rac1 activity
medications ; heart failure
cardiovascular death ; urgent cardiac transplant
circulating mediator of insulin resistance ; human monocytes ; inflammatory stimuli
Heart failure ; HF ; Latin America ;LA
heart failure ; medicine ; atheromatous coronary disease
palliative
HF hospitalization ; cRT
rehospitalization ; medicare fee-for-service ; skilled nursing facilities
HFpEF




psoriasis
ischemic ; ischemic heart failure
stress conditions ; maladaptive remodelling
heart failure ; Emergency Department ;ED ; ED
Intravenous iron
RV dysfunction ; weight loss ; body composition ; HF
PD ; complications ; therapy
diastolic dysfunction ; hFPEF
chrmatin-associated proteins ; chromatin structure ; DNA
NT-probNP ; HF patient plasma ; immunoprecipitation
ventricle overload ; stroke volume ; ventricular ejection time ; lVET
adrenergic receptor blockade ; heart failure ;HF
congestive heart failure
mitochondrial structure ; sarcomeric microstructure
CHF patients ; emergency department ;ED
mortality ; LCx ; LAD ; two-vessel disease model
pPR ; aCR ; CMS
gut ; inflammation ; heart failure
practice-level
robot-assisted gait therapy ; Lokomat® system in heart failure
implantable cardioverter-defibrillator deactivation
pulmonary hypertension ;PH ; heart failure
lVET ; ICU

Cardiac failure ; diabetes ; heart failure
ET ; CHF-NYha-IIIb ; HDL function
catheter ablation ; antiarrhythmic drugs
therapeutic interruption ; neurohormonal systems
implantration ; heart rate ; renal
microRNAs ;miRNAs ; heart failure
Beta-blocker dose
QT variability ; QTV
implanted New Zealand White rabbits ; renal DNx ; pacing-induced CHF
ambulatory HF patients ; left ventricular ejection fraction
implant-HF ; chronic heart failure Chronic heart failure
physician follow-up after discharge
dialysis patients ; echocardiographic
zf1 rats ; heart failure ; preserved ejection fraction
transoesophageal echocardiography
mutant mice overexpressing Hand2 ; heart muscle cells ; pathological hypertrophy
heart ; adipose tissue ; cachectic heart failure
lVET ; precapillary PH ; heart failure
heart magnetic resonance imaging ; chelation choices ; heart disease ; thalassaemia
mRI ; tidal respiration ; myocardial t1 ; swine ; heart failure
technologies

cardiovascular disease
Rhythm control therapy
proteins

AMI mortality rates
psoriasis ; cardiovascular disease ;CVd
eseptal
système proteomics ; cardiac chromatin ; nucleolin ; regulator of growth ; cellular plasticity ; cardiomyocytes
cardiac dysfunction ; subcellular alterations ; metoprolol ; heart failure ; myocardial infarction
Hemoglobin ; health status ; chronic heart failure ; HF-ACtion
RAS-blocker uptitration ; clinical outcome ; hFrEF ; HFpEF
Myocardial collagen ; collagen cross-linking ; titin isoforms
Cardiac magnetic resonance postcontrast ; heart failure ; ejection fraction
diastolic dysfunction ; filling pressures ; doppler echocardiography
cardiovascular disease

early medical management ; HF
cardiac remodeling ; heart failure
frailty ; risk ; heart failure ;HF
heart failure ; bisphosphonates
figure ; beta-blocker
cardiomyocytes ; norepinephrine-induced hypertrophic responses
index admission
Plasma ; HF
alendronate
transduction pathways

GDMT ; BAT
heart failure ; CLCNKA sNP
clinical diastolic dysfunction
aCS ; oHT bridged to transplant ; MT ; VAD
RAS- ; β-blocker dose
regulation of feeding ; anti- inflammatory effects ; CHF
PRInciPAL FINDINGs ; HF ; CMS
Bax ; bcl-2 proteins
HF ; rheumatoid arthritis ;RA
Blocker-induced enhancement ; cardiac angiogenesis
Fontan ;SAF
natriuretic peptides
sandwich AlphaLISa ; immunoassays ; NT-probNP
cardiotoxicity ; doxorubicin
ventricular ; ejection fraction
implantable cardioverter-defibrillator deactivation
sinus rhythm ; antiplatelet agents ; anticoagulants
c-statistics ; biological phenotype ; deficit index
lifesaving drugs ; HF ; fraction ;HFrEF
LV diastolic dysfunction
ambulatory ICD patients ; predictor ; mortality
fes ; preserved ejection fraction ;HFpEF
cardiac benign tumors ; left atrium
nicorandil ; cytotoxic effect ; doxorubicin ; Ehrlich carcinoma
Gastrointestinal bleeding
ARNI inhibitors ;angiotensin-receptor neprilysin inhibitors
Renal denervation ;DNx ; CHF
physician follow-up after discharge ; physician continuity
hyperkalemia ; acute kidney injury ; spironolactone
Heart failure ; preserved ejection fraction ; hfEF ; cardiovascular reserve
heart failure ; left atrial pressure
Mammalian enabled ;Mena ; cytoskeletal actin dynamics ; heart failure ;HF
refractory congestive heart failure ; peritoneal dialysis
MT ; VAD groups ; aCS
bNP ; NT-proBNP ; coronary artery disease ;CAD

aerobic capacity ; left-hand grip strength ; body weight
clinical variables
circulating forms ; NT-proBNP

Functional mitral stenosis ;MS ; ring annuloplasty ; ischemic mitral regurgitation ;MR
heart failure-related hospitalization ; ventricular ejection
Kansas City Cardiomyopathy ; heart failure ; ejection fraction
heart failure ; preserved ejection fraction ; hff
lean ZSF1 group ; obese ZSF1 ; hypertensive ; diabetic
tissue doppler imaging ; ventricular filling pressure ; patients ; systolic heart failure
Heart failure ; preserved ejection fraction ;HFpEF ; cardiovascular morbidity
myocardial Pde2 ; intracellular antiadrenergic therapeutic strategy ; HF
ICU ; precapillary PH ; heart failure
Myocardial loss ; iRS1 ; iRS2 ; heart failure ; maPK ; insulin resistance
heart failure mice ; hypertensive heart ; angiotensin II infusion ; nephrectomy ; salt loading
transfusions
PVf ; PB cycle
sST2 ; cardiovascular event
eCG parameters ; cRT
Remote monitoring ;RM
RV dysfunction ; cardiac cachexia
chronic heart failure
HF
figure ; joint effect
benefits ; spironolactone
carotid intima-media ; psoriasis
coronary occlusion ; collateral growth
Mechanical dyssynchrony ; QRS complex
pharmacologic treatment
IE ; heart failure ;HF ; cRT-d
breast cancer patients ; trastuzumb-related CHF
pde2 ; failing hearts ; implantation
anemic ; iron-deficient adult patients ; heart disease
point-of-care systems ; NP levels ; ED ; communauté outpatient settings ; acute heart failure
EO-CFUs ; mortality
trastuzumab ; CHF ; nontrastuzumab
eGFR ; diuretics ; uncontrolled hypertension ; ESRD
heart failure
acute heart failure ; aHF
psoriasis patients ; psoriasis
HF remodeling aspects ; EMd ; dyssynchronous failing heart
HR reduction ; beta-blocker therapy
anthracycline-related congestive heart failure ; haematopoietic cell transplantation
HF ; hypertension ; vasodilators ; diuretics
aldosterone antagonist
angiogenesis ; post-myocardial infarction heart ; heart failure
heart failure ; ejection fraction ; myocardial infarction
lVAS
HDL function ; CHF ; ET ; HDL-mediated vascular effects
HF ; HF ; HF mortality
physician adherence ; HF
hff
cardiac disease ; heart failure
black race ; HF hospitalization ; cardiovascular mortality
coronary artery disease ; systolic heart failure
arterial compliance ;TAC ; end-systolic elastance ; ees
Renal dysfunction ; cardiovascular events
isoprenaline infusion ; SDQT ; hNorm ; HF
cardiovascular ; diabetes mellitus ; atrial fibrillation ; coronary artery disease ; HFpEF
Renal dysfunction ; long-term mortality ; myocardial infarction ; coronary artery bypass grafting ;CABG
biventricular support ; HeartMate II lVAD ; CentriMag RVAD
Pyridostigmine ; vascular endothelial growth ; ventricle ; myocardial angiogenesis
implants ; transseptal catheterisation ; transoesophageal echocardiographic guidance
dopamine ; nesiritide
clinician
biomedical reasons
ERC ; pure epicatechin
Care management coupled ; content-driven telehealth technologie ; health outcomes ; Medicare beneficiaries
Ea ; TAC ; HR ; ees ; ivabradine-
HF
CHF ; Diseases
MEDLINE ; EMBASE ; cochrane databases ; clinical trial registries ; technical advisors
egFR ; VAD group ; ECmo
idiopathic dilated cardiomyopathy
cardiac growth ; plasticity ; disease recapitulates ; chromatin remodeling
Robot-assisted gait therapy ; Lokomat® System ; heart failure
baseline CRF ; HF mortality risk ; HF
RV dysfunction ; figure
myocardium displays ; pka
elastic N2Bus segment ; PEvK
proteomics ; chromatin-associated proteins ; detergent
cXL-1020 converts ; hno ; inactive cXL-1051
arterial elastance ; pulsatile afterload ; heart ; pressure
pharmacologic management ; acute HF
Nicorandil ameliorates mitochondrial dysfunction ; doxorubicin-induced heart failure ; rats
HeartMate ; left ventricular assist system ; lVAS
implantable cardioverter-defibrillator
Self-Care of Heart Failure Index ;SCHFI
atrial fibrillation ; carvedilol
heart failure ; mechanical support devices ; Cardiology-cardiovascular Surgery ; Heart failure
ms ; Killip class
management ; end stage heart failure ; public health
implantation
functional MS ; valve plasty ; degenerative MR ; LV
tNF antagonists ; HF hospital admissions ; nbDMARDs ; RA
physician adherence ; class I recommendations

mortality
exercise ; diet
grs ; h ; fréquence ; CV

epidemiologie ; myocardial infarction ;MI ; heart failure ;HF
Heart rate reduction ; exercise ; heart failure ; ejection fraction ; beta-blocker hypo-response
Isoelectric focusing ; RIα ; phosphorylation sites
baseline NT-proBNP ; MR-proANp ; MR-proADm
mADIt-cRT ; multicenter Automatic Defibrillator implantation ; Cardiac resynchronization Therapy ; NCT
natriuretic peptide ; bNP ; creatinine ; natremia
hypertension ; nephropathy ; congestive heart failure
SDQT ; SD ; RR ; index ; QTV ; heart rate variability
cardiac magnetic resonance imaging ; invasive hemodynamic assessments
HF ; PAf biosynthetic enzymes ; lyso-PAf-AT
cardiac events
sST2/low-dose BB
HF complicating AMI ; mortality
LV ejection fraction
zebrafish ; nucleolin ; genomic reprogramming
Physician volume ; HF ; noncardiologist physicians
CHF visit ; ED visits ; CHF patients intubated
Logistic regression models
egFR ; VAD group ; ECmo+VAD group ; renal function
eseptal ; eemean ; QRs width
implant ; gastrointestinal bleeding
hospital ; heart failure
diuretics ; modulate HF-related morbidity
hospital stay ; congestive heart failure
IVc occlusion ; CO correlated ; twist ; apical rotation ; RS synchrony ; CS
emergency department ; acute heart failure clinical trials
heart failure ;HF
carvedilol ; metoprolol ; heart failure patients ; devices
BET bromodomain-containing protein ;BRd4
in-trial resource utilization ; unit costs ; Québec Health Insurance Board ; disease-specific costs ; Ontario Case Costing Initiative
mitral valve plasty ; degenerative mitral regurgitation
intravenous iron
Erythropoiesis-stimulating agents ; anemia ; heart
public health ; air pollution ; urban ; industrial areas ; cardiovascular health
molecular biomarkers ; HF
cardiopulmonary ; life score ; muscular strength ; peak quadriceps force
HF ;heart failure ; t2d ; type 2 diabetes ; Skm ;skeletal muscle
Morbidity ; mortality ; HFpEF
HF rats ; pyridostigmine ; basal heart rate ; vagal ; sympathetic control
idiopathic dilated cardiomyopathy ; tuscany
eCG ; congenital accessory pathways ; ion channelopathies ; cardiomyopathy
RAS ; neprilysin inhibition ; chronic heart failure ; systolic dysfunction
AF ablation
ejection fraction
echocardiographic score ; cRT
économique models ; lVAD
vent failure ; pediatric mechanical cardiac

gadolinium-chelate contrast agent
Medicare inpatient ; HF admissions ; acute care hospitals
HF ; preserved ejection fraction ; pEF ; uptitration
mouse HF ; hh ; salt loading ; uninephrectomy ; ANG II infusion
DAPc ;dystrophin-associated protein complex ; sarcomeric microstructure
dopamine ; nesiritide ; acute heart failure ; renal dysfunction ; acute heart failure
catheter ablation ; atrial fibrillation ; heart failure ; ejection fraction
Myocardial titin hypophosphorylation ; heart failure ; ejection fraction ; rat metabolic risk
Cardiac insulin-resistance ; mitochondrial energy production ; systolic heart failure ; pressure-overload hypertrophy
If-channel inhibition ; hemodynamic status ; exercise tolerance ; heart failure ; preserved ejection fraction
RV failure ; ventricular dysfunction
Chronic heart failure ; transforming growth factor beta-dependent ; functional decline ; atrial explant-derived c-Kit
Mortality ; hospital days ; emergency department ;ED
HF ; MI ; preserved ; ejection fraction ;EF
implantation ; heart failure
HeartMate II lVAD ; temporary CentriMag RVAD
HFpEF ; kccq
baseline serum creatinine ; ml ; serum potassium
PD ; diuretic response ; edema ; functional class
echocardiographic predictors ; response ; cardiac resynchronization therapy ; cRT
circulating NT-proBNP ; antibodies ; nonglycosylated
University of Connecticut Heart Failure Center ; cardiologist ; heart failure nurse
anemia ; chronic heart failure ;HF
Hum- retn mice ; cardiac mRNA ; inflammatory ; cell adhesion genes ; Retn ; mice
chromatin subproteomes ; heart failure
nbDMARD ; tNF antagonist
hf ; exercise performance ; resting HR ; bpm ; beta-blocker therapy
XO inhibition ; cardiomyocyte bioenergetics ; LV ; chronic ACF ; rat
heart failure ; heart failure nurses ; cardiology services
heart failure ;HF ; cardiopulmonary exercise ; anaerobic threshold
renal dysfunction ; stroke ; myocardial infarction ; heart failure ; CABG
cox hazard models ; temps ; ESRD ; death ; ESRD
randomised-controlled trials ;RCts
pyridostigmine administration ; methylatropine ; propranolol ; cardiac sympathovagal balance
PAf ; metabolic enzymes ; heart failure
trastuzumab ; adjuvant setting ; cardiotoxicity ; congestive heart failure
carvedilol ; thromboembolic events ; heart failure ; β2-receptor haplotype
Phosphodiesterase-2 ; human failing hearts ; blunts beta-adrenergic responses ; cardiomyocytes
echocardiographic ; natriuretic peptide ; inflammatory markers
myosin binding protein-C phosphorylation ; Ser23/24 troponin I phosphorylation ; HF
uPR ; protein kinase ; ER kinase ; calreticulin ; CHOp ; HF
HF rats ; pyridostigmine ; stroke volume ; ejection fraction ; cardiac output ; contractility ; ventricle

deactivation
nutritional abnormalities
coût ; high-volume physicians
doxorubicin ; ip ; serum resistin ; Hum-retn mice
pigs ; inferior vena cava ;IVc ; CO
direct ; rheumatic ; MS
hCT CHF
middle-aged recreational athletes ; sudden cardiac deaths
oxygen ; pulse
dialysis-dependent patients ; HF ; cRT implantation
RV ; RV dysfunction
CHF ; infarcted animals ; ventricle end-diastolic pressure ; hg
Womens Health Initiative ; HF
économique climate ; NHs ; behavioural-change ; chronic disease
aldosterone receptor antagonists ; morbidity ; mortality ; systolic heart failure
CV ; non-fatal stroke ; heart failure
biomarkers ; molecular dysfunction
air pollution ; cardiovascular health
VAD group ; ECmo+VAD group ; ECmo group
biomarkers ; heart failure
grs ; index beat ; CV ; cox proportional hazards
risk ; c statistic ; discrimination
rhythm control therapy ; AF ; cardiovascular complications
hearts ; Mena ; cardiac injury ; Mena ; HF pathophysiology
sCN5a transcript ; uPR ; downregulation ; cardiac genes ; HF
lipolysis ; energy expenditure ; natriuretic peptides ;NPs ; CC
cox proportional hazards models ; health behaviors ; health status
tAPse ; PASp
ventricular ; insertion ; left ventricular assist device ; lVAD
albumin ; inflammation ; hepatic function ; implantation
kccq ; Kaplan-meier curves ; death
Olmsted County ; Minnesota ; MI ; HF
risk ; medical hospitalization ; HF
sensitivity ; CAD ; sensitivity
vascular endothelial growth factor ;VEGF ; transition ; compensatory hypertrophy
ventricular ejection fraction ; long-term mortality ; heart Failure ; ISrael
neurohumoral blockers ; HF
odds ratio ;hazard ratio ; HF ; AMI
Testosterone therapy ; exercise rehabilitation ; patients ; chronic heart failure ; testosterone status
health Buddy Program ; chronic obstructive pulmonary disease ; mortality ; congestive heart failure
RAS ; doppler ultrasonography ; computed tomographic angiography ; magnetic resonance angiography
multicenter Automatic Defibrillator implantation Trial-Cardiac Resynchronization Therapy
nicorandil ; cardioprotection ; apoptotic signaling pathway ; DNA fragmentation ; mitochondrial ultrastructural changes
proteomics ; pressure-overload-induced heart failure ; mitochondrial-targeted peptides
AMI ; heart failure ; kidney infection ; UTI
renal underperfusion ; renin- angiotensin-aldosterone
hypoalbuminemia ; postoperative mortality ; left ventricular assist device ; lVAD
HR dynamics ; temps-domain ; HR variability
cRT-d ; IE ; defibrillator-only therapy
patients
HF ; index AMI
apoptosis ; heart failure
BETs ; transcriptional pause release ; transcription
lVAD ; transplantation eligibility status
LVEF
uPR ; na+ channel mRNA splice ; reduction ; cardiac na+ current ; HF
diuretic efficacy ; neurohormonal activation
eCG ; atherosclerotic CAD ; sudden cardiac death
diabetes mellitus ; metabolic risk factors ; heart failure ; ejection fraction
Cardiopulmonary exercise ; echocardiographic assessment ; myocardial function ; left ventricular filling
percutaneous coronary revascularization ; hemodynamically
therapy ; atrial fibrillation ; atrial tachyarrhythmias ; ATP
speckle tracking echocardiography ; ste ; biVP ; ventricular pressure overload ;RVPO
HR reduction
fractional shortening ; lung weight
implantation ; programmed cell death
rad variant ; congestive heart failure
incident systolic heart failure ; spironolactone
Trastuzumab ; CHF ; nontrastuzumab ;hazard ratio ;HR
Fontan failure ; circulatory derangement ; hemodynamic ; portal hypertension ; cardiac output
perk inhibition ; kv ; mRNA ; mRNA splice
bottleneck stent ; myocardial infarction ; antiplatelet medication
sex ; EF ; bNP ; HF ; bNP ; sex ; EF
atrial fibrillation ;AF ; heart failure ;HF ; stroke ; anticoagulation
echocardiographic score ; LV reverse remodeling
salt loading ; uninephrectomy ; ANG II infusion mouse ; cardiac ; mice ; HF
Mena expression ; HF ; mena ; cardiac pathophysiology
LVEF ; long-term mortality ; acute decompensated HF
implantation ; atrial fibrillation ; Stroke prevention Trial
benefits ; controlled randomized trials
NP measurement ; POC measurement ; NPs
RECENT FINDINGs
patients ; high-volume physicians

cardiac hypertrophy ; nucleolin
figure
myocardial DD ; muscle strip stiffness ; titin hypophosphor
cardiovascular mortality ; hospitalization ; heart failure
anaerobic metabolism
idiopathic dilated cardiomyopathy
fibrosis ; heart failure myocardial tissue ; left ventricular tissue
Kansas City Cardiomyopathy Questionnaire ; kccq ; HF ; EF ; HFpEF
Blood pressure ; arm cuff ; stroke volume ; ejection fraction ; end-diastolic volume ; echocardiography
biventricular support ; HeartMate II lVAD ; CentriMag right ventricular assist device ;RVAD
annular plane systolic excursion ; pulmonary arterial systolic pressure ; heart failure ; ventricular contractile
ventricular ;RV ; body composition ; heart failure ;HF
College of Cardiology ;American Heart Association guidelines ; management ; patients ; RAS
Frailty ; heart failure ;HF ; biological phenotype ; deficits
functional MS ; valve plasty ; annular size reduction ; degenerative MR ; LV
implantable cardioverter-defibrillator deactivation
EO-cFUs ; CD34 ;vegFR2
functional MS ; valve plasty ; degenerative MR ; LV
HF
ventricular assist device ;VAD ; extracorporeal membrane oxygenation ;ECMO
implant ; Caucasian ; sNP rs10927887 ; renal chloride channel gene ;CLCNKA
Circulating progenitor cells ; cPCs ; endothelial repair ; cardiovascular
HF-ACTION cohort ; hgb ; baseline HRQoL ; kccq
pathological remodelling ; heart ; cardiac hypertrophy ; HF ; fibrosis
NT-probNP ; plasma ; dyspnea ; left ventricular dysfunction ; ED
contractile function ; LV dilatation ; end-diastolic pressure ;wall stress ; lung weight
LV remodeling ; diastolic properties ; XO inhibition
virtual cohorts ; resource use ; coût-effectiveness
implants
blood pressure control ; lipid-lowering therapy ; smoking cessation ; RAS
SDQT ; HFVT ; HFVT ; hNorm group ; fixed-rate atrial pacing
bt ; DT ; coût-effectiveness ; bt
expenditure ; health per capita ; gross national income per capita ; HF
temps-dependent analysis ; IEs ; cRT-d ; heart failure
bNP ; inhospital mortality
diffuse myocardial changes ; heart failure ; contrast agent ; breath-holding
AF ; pharmaceuticals
RAS- ; β-blocker uptitrations ; hFrEF ; HFpEF
cardiac magnetic resonance ; amyloidotic pattern ; multiple myeloma
HFpEF ; echo-Doppler cardiography ; invasive haemodynamic assessment
DASH ; diastolic function ; ventricular-arterial coupling ; hypertensive heart failure ; ejection fraction
Vascular endothelial growth factor blockade ; beta-blocker therapy ; cardiac function ; angiogenesis ; remodeling in heart failure
implantable cardioverter-defibrillators ;ICds ; cardiac resynchronization therapy ; cRT
frail ; biological
hff
implantable cardioverter defibrillator-CRT
mDC
embryonic gene programs ; pathological heart disease ; transcription factors
acute heart failure ; aHF
RM
skeletal muscle sarcomere structure ; heart failure ; diabetes ; epicatechin-rich cocoa
QRs morphology ; effectiveness ; cardiac resynchronization therapy ; cRT
implantation ; hg ; pasp
sst2/low-dose BB ; sST2/high-dose ; cardiovascular events
mitochondrial complex V activity ; aAC ; phosphocreatine ; ATP
eplerenone ; HF-REf ; hyperkalemia ; WRF
centrifugal flow pump ; hemocompatibility ; magnetically levitated rotor ; blood-flow ; artificial pulse
Physician volume ; patients ; medically managed diseases
heart rate ;HR ; ivabradine ; patients ; systolic heart failure
biomedical treatment ; CHm ; biomedical treatment ; dCM ; heart
Cardiovascular Outcomes ; Renal Atherosclerotic Lesions ;CORAL ; stenting in RAS
Yorkshire swine ; implanted ; pacemakers ; ventricularly paced ; heart failure
multiparametric echocardiographic score ; reverse remodeling ; cRT
Mediterranean ; Dietary Approaches ; Stop hypertension ;DASh ; mortality ; postmenopausal women ; HF
therapeutic left-to-right interatrial shunting ; heart failure
mortality ; heart failure ;HF ; implantable cardioverter defibrillators ;ICds
heart failure ; hypertension ; mitral regurgitation ; mitral stenosis
cardioprotective signaling ; myocardium ; biomarker in heart failure ;HF
cardiovascular death ; stroke ; heart failure ; myocardial infarction
MI ; metoprolol ; plasma norepinephrine ; dopamine ; epinephrine
pulmonary hypertension ; ventricular contractile reserve
implantable cardioverter-defibrillator ; Heart Function Clinic ; University Health Network ;Toronto
perk activation destabilized sCN5a ; kv4.3 channel mRNAs ; transient receptor potential cation ; mdp ; mRNA
Cardiac-resynchronization therapy ; cRT ; morbidity ; mortality ; chronic systolic heart failure
renin-angiotensin-aldosterone ; sympathetic nervous systems
NP
conditions ; urban academic medical center
quality of life ; functional capacity
électronique databases ; MEDLINE ; EMBAse ; PsycINFO
echocardiography ; cardiac diameters ; b-treated ; rats
implantable cardioverter defibrillator-CRT
patient-level regression ; mortality ; readmissions
international Right Heart Foundation
HF ; HF ; HF epidemiologie ; SH ; cd ; rheumatic fever
mice ; cardiac myocyte-specific Mena
HFpEF ; diastolic filling time ; heart rate
medications ; heart failure ; ejection fraction
chronic heart failure ;HF ; hemodynamic disorder ; syndrome ; dysfunction
caloric restriction ;diet ; aerobic exercise training ;exercise ; QOL ; hff
antiplatelet agents ; anticoagulants
systolic HF ; cXL ; left ; right heart filling pressures ; systemic vascular resistance ; cardiac ; stroke

figure ; ff ;cc
therapeutic strategy ; AF ; patients ; severe heart failure
cardiac hypertrophy secondary to pressure-overload ; abdominal aortic constriction
patients ; heart failure ; hospital discharge
intermacs ; interagency Registry ; Mechanically Assisted Circulatory Support
na+ channels ; unfolded protein response ; uPR ; electric remodeling ; HF
ankle-brachial index ; pulse-wave velocity ; coronary artery calcium scores
myofiber dynamics ; myofiber shortening ; emd ; dyssynchronous HF
Fontan failure ; hemodynamically ; heart failure ; systemic vascular resistance ; sVR ; cardiac index
allopurinol ; LV contractile function ; efficiency ; XO-mediated ROS ; myofilament
hgb ; kccq scales ; hgb ; exercise training ; HRQoL
ventricular ejection fraction ; ventricular diastolic end diameter
β-adrenergic receptor blocker therapy ; myocardial perfusion ; neoangiogenesis ; failing heart
ventricular ejection fraction ; heart failure ; HFpEF
ventricular hypertrophy ; heart failure ; preserved ejection fraction
implant
therapy
ET ; HDL-mediated protective effects ; molecular pathways ; chronic heart failure ;CHf
physique activity ; cRF ; HF mortality
metabolic exercise ; cardiac ; kidney index score
heart failure ; refill ; etidronate ; alendronate
rehospitalization ; Medicare hospital claims ; Medicare ; post-acute care transfer policy
physicians ; patients ; advanced heart failure
bNP ; diastolic dysfunction
implantg techniques ; systolic function ; HFpEF
sCN5a ; angII ; hypoxia ; uPR ; downregulation
NT-probNP assay ; nonterminal epitopes ; central glycosylated
g-protein-coupled receptor kinase-2
AAs ; HF ; hyperkalemia ; hypokalemia ; spironolactone
HF ; mortality ; hazard ratio
dopamine ; nesiritide ; decongestion ; renal
alendronate ; etidronate- ; raloxifene-tre
clinical trials
implantable cardioverter defibrillator-CRT ; LBBB ; QRs duration
kccq domains ; HFpEF
literature ; anemia ; iron deficiency ; MEDLINE ; cochrane Library
hART ; HF ; HF ; HF ; hrEF
bone morphogenetic protein ; rRNA transcription ; chromatin
ventricular assist devices ; lVADs ; patients ; advanced heart failure ; pump
systolic HF ; Danish Heart Failure database ; ESRD ; Danish Registry on Dialysis
extracellular matrix ; left ventricular biopsies ; tissueFAXs technologie correlated
resistin ; anthracycline-induced cardiotoxicity ; heart failure
actin cytoskeleton ; mitochondrial function ; intermediate metabolism ; glycolysis/gluconeogenesis ; citrate cycle
implantation ; amino-terminal ; natriuretic peptide
conscious dogs ; tachypacing-induced HF ; contractility ; end-systolic elastance ; venoarterial dilation
Chemotherapy ; trastuzumab use ; comorbidities ; CHF ; international Classification of Diseases ; healthcare Common Procedure codes
contemporary heart failure ;HF ; ventricular ejection fraction ;LVEF
performance ; hospitals
sst2/high-dose BB
saxagliptin ; sitagliptin
myocardial collagen
Sprague-Dawley rats ; sham ; aCF ; allopurinol
cardiac plasma membrane ; s1PR1 ; deleterious β1AR overstimulation ; heart failure
neurohormones ; adipokines ; body composition ; CC ; fat free mass ;fm ; fat mass ;FM
magnetically levitated lVAS ; mortality ; Seattle Heart Failure
biomedical treatment ; CHm ; biomedical treatment ; dCM ; heart failure
biventricular pacing ; biVP ; cardiac output ;co ; cardiac surgery
Myocyte hypertrophy ; heart failure ; gene expression
expression ; mistargeting ; regulation ; rad Q66p ; RGK protein
creatinine ; bNP ; furosemide dose ; oxygen flow ; dobutamine ; norepinephrine
AlphaLISa immunoassays ; antibodies ; n ; c termini ; circulating NT-probNP
New York Heart Association ;NYHA ; chronic heart failure ; reduced ejection fraction
catheter ablation ; AF ; compensated HFPEF ; left ventricular ;LV
implantation
ct group ; hazard ratio
cardiomyocytes ; mechanical ; humoral stimuli ; myocardium
BB therapy ; patients ; chronic heart failure
biventricular support
hno donor ; myocardial function ; HF
TUnel assay ; apoptotic cells
passage ; length-force relationship ; RV ; LV
ESRD ; outpatients ; systolic HF
congestive heart failure ; Midwestern state ; South Dakota
Swedish national inpatient Registry ; rehospitalization ; stroke ; myocardial infarction ; heart failure
implantation ; LV assist device implantation ; heart
race ; exercise training ; chronic heart failure ; Heart Failure ; controlled Trial Investigating Outcomes ; Exercise TraiNing ;HF-ACTION
Hospitalized Heart Failure ; Saxagliptin ; sitagliptin ; antihyperglycemic Drugs
interclass correlation coefficient ;ICc ; kappa coefficient ; md
Nicorandil ; phosphocreatine ; adenine nucleotides ; mitochondrial oxidative phosphorylation capacity ; creatine kinase activity
biological phenotype ; deficit index ; medical records
Cardiology practices ; national Cardiovascular Disease Registry practice Innovation ; Clinical Excellence
tachycardia ; intravenous atropine ; cardiac vagal tone ; CHF-DNx ; CHF-INV
CHF ; cardiac explant c-Kit ; progenitors
transitions of care
surgically induced myocardial infarction ; heart failure rats ; bisoprolol
sts HH ; t ; medical support ; office hours ; mortality ; heart failure
Peritoneal dialysis ;PD ; diuretic resistant volume overload in heart failure ;HF
SDQT ; HFVT ; hNorm ; β-adrenoceptor blockade ; esmolol
heart failure ; preserved ejection fraction ; hff ; heart failure ; overweight ; obese
peripheral muscle pump ; cardiac filling ; subpulmonary ventricle ; Fontan circulation
figure ; heart failure ;HF ; acute myocardial infarction ; pneumonia
Peripheral artery disease ;PAD ; heart failure ;HF ; HF ; PAD
echocardiographic score ; LV reverse remodeling ; LV end-systolic volume
Renal dysfunction ; heart failure ;HF ; end-stage renal disease ;ESRD
hno donor ; cXL-1020) ; intact hearts ; heart failure ;HF

protocol-driven POC testing ; NP ; consultation ; ED ; throughput ; disposition of at-risk patients
shuttle walk test ; body mass ; kg ; hand grip strength
physician volume ; mortality
capillary ; coronary perfusion ; b-treated ; ad-flk rats ; b-treated
race ; long-term outcomes ; chronic heart failure ;HF
ms ; dynamique ; annular MS ; fixed ring size
heart failure ; CHARM programme ;Candesartan in Heart Failure Assessment ; Mortality ; Morbidity
interatrial shunting ; patients ; heart failure ; ejection fraction
heart failure ; left ventricular ejection ; spironolactone ; Kaiser Permanente Northern California
Nicorandil ; heart rate ; aortic blood flow ; mitochondrial oxidative stress ; doxorubicin cardiotoxicity
aldosterone antagonist therapy ; chronic advanced heart failure patients ; post-myocardial infarction heart failure patients
myocardial extracellular matrix ; cardiac magnetic resonance ; pathobiology/pathophysiology
bmi ; heart rate ; rhythm ; lying ; standing blood pressure ; valvular disease ; pulmonary congestion
renal dysfunction ; cardiovascular events ;stroke ; myocardial infarction ; heart failure
Troponin ; n-terminal pro-B-type natriuretic peptide ; biomarker ; heart failure risk ; atherosclerosis risk
cell senescence ; active ; malignancies ; cancer ; prostate ; colon ; osteoporosis
pediatric Fontan ;PF
mRI-based models ; dyssynchronous nonfailing ; HF canine electromechanics
chronic heart failure ;CHf ; explant-derived progenitor cells
anemia ; HF ; health-related quality of life ;HRQoL
Lancet ; air pollution ; heart failure
ventricular assist devices ; cardiac nurses ; gastrointestinal bleeding
American College of Physicians ; aCP
cardiac transplant ;ECCT
m-induced decreases ; septum ;systolic
HR variability ; mortality ; AMI ; CHF
BAT ; implantal pro-brain natriuretic peptide
prospective HF registry ; HF ; EF ; HFpEF
économique Analysis ; Patient Management Interventions in Heart Failure Cost-Effectiveness Model ; disease management programs in heart failure
hff ; caloric restriction ; aerobic exercise ; VO2
RV failure ; chronic pulmonary arterial hypertension ;PAh ; acute pulmonary embolism
SDQT-to-SDRR ratio ; HFVT ; hNorm
ventricular structure ; geometry ; fiber ;sheet orientation ; handling ; slowed conduction ; wall stiff
rad Q66p ; cardiomyopathy
implants ; cardiovascular event
serum resistin ; anthracycline-containing chemotherapy
RV failure ; pulmonary embolism
Exercise ; Medical Therapies ; Cardiac Function ; Shortness of Breath Due to Lung Congestion
tachycardic response ; methylatropine ; vagal tone ; bradycardic ; propranolol
mortality ; cardiovascular mortality ;HF hospitalization
spironolactone ; death ; hyperkalemia ; acute kidney injury
mitochondrial oxidative phosphorylation capacity ; creatine kinase activity ; oxidative stress markers
Fractional flow reserve ; positron emission tomography imaging ; ischemia ; bottleneck stenting ; left ventricle ; proximal LAD
cardiac resynchronization therapy ; cRT ; mild heart failure ;HF ; QRs prolongation ; ejection fraction ;EF
Neprilysin inhibitors ; natriuretic peptide system ; breakdown ; atrial natriuretic peptide ; b-type natriuretic peptide
electrical stimulation ; peripheral muscles ; endothelial function ; heart failure ; ventricular ejection fraction
renin-angiotensin system blocker ; beta-blocker therapy ; heart failure
Chinese herbal medicine ;CHm ; adjunctive treatment ; dilated cardiomyopathy ;DCm ; heart failure
preoperative hypoalbuminemia
nurse assessment of cognitive impairment ; hospitalization ; physician ; discharge ; elderly patients ; heart failure
bisphosphonates ; alendronate ; etidronate ; risk of heart failure
Baroreflex sensitivity ; time domain heart rate variability ;HRV ; CHF-INV ; sham-INv ; sham levels ; renal DNx
patients ; advanced heart failure ;heart team
electrical activation ; dyssynchronous heart failure ;HF ; electromechanical behavior
HF-ACTION ; HF ; HF ; ejection fraction
hypertension ; hg ; diabetes mellitus ; systolic
TAPse ; PASp ; nonsurvivors ; hFrEF ; HFpEF
in vivo inhibition ; mir-25 ; cardiac dysfunction ; murine myocardium to heart failure
cardioprotective effect ; nicorandil ; hemodynamic alterations ; mitochondrial dysfunction ; doxorubicin
haematopoietic cell transplantation ; hCT ; congestive heart failure ;CHf ; hCT ; anthracyclines
NT-probNP ; mortality ; acute HF
epigenetic ; proteins ;histone acetyltransferases ; epigenetic ;erasers ;histone deacetylases ; cardiac development ; disease
carvedilol ; nonselective β-blocker ; selective β-blocker metoprolol ; thromboembolic events ; heart failure
cardiac transplant survival
qualité ; HF ; AMI ; pna ; mortality
patients ; heart failure ;HF
implanting ; arrhythmia substrate ; AMI ; HR variability
doxorubicin-induced cardiotoxicity ; Hum-Retn mice ; littermate controls ; human resistin
hypertension ; compensated HFPEF ; DASh/sRD ; sodium ; kcal
emd ; dyssynchronous HF
diastolic dysfunction ; pathophysiology ; HFpEF
ejection fraction ; cardiac index ; inotropes ; inotrope-dependent
lipoprotein ;HDL ; endothelial-protective effects ; endothelial cell ;EC ; nitric oxide ;NO
hHF ; saxagliptin ; sitagliptin ; antihyperglycemic agents
ischemic ; ischemic heart failure ; healthy control ; heart failure
insulin resistance ; type 2 diabetes ; insulin receptor substrates ;IRs1 ; iRS2 ; insulin-signaling components ; cellular metabolism
admission to discharge ; hospitalized older adults ; heart failure ;HF ; Nursing Outcomes Classification
fluo-cAMP binding ; wild type ; phosphomimic Ser77 ; ser83 mutant RIα proteins ; double mutant ; WT
preoperative albumin ; mortality ; implantation
systolic heart failure ; QRs duration ; cRT ; mortality
cox regression models ; propensity score decile ; oral glucocorticoid ; HF ; loop diuretics
Functional electrical stimulation ; fes ; exercise capacity ; emotional stress ; endothelial function ; chronic heart failure ; systolic function
dialysis patients ; HF hospitalization
reoperation ; bleeding ; driveline infection ; gastrointestinal bleeding ; debilitating stroke
Beta blockers ; mortality ; readmissions in heart failure ; ejection fraction ; hrEF ; heart rate ;HR
dyssynchronous HF ; electromechanical delay ; emd ; myocyte depolarization ; myofiber
QRs morphology ; cardiac resynchronization therapy ; resynchronization-Defibrillation ; Ambulatory Heart Failure Trial ;RAFT
statistical standards ; biomarker-guided clinical trial ; multimarker-based strategy
abnormal liver texture ; nodularity
transplant ineligible patients ; PD ; HF volume management
Frailty ; biological phenotype ; weak grip strength ; physical exhaustion
cRT-d ; IE ; IC ; cRT-d ; IEs
volume EDs ; heart failure
acute right heart failure ; therapy refractory cardiogenic shock ; heart ; extra corporeal membrane oxygenation ; cPR ; ICU
right atrial myxoma ; pulmonary arteries ; right atrial mass removal ; pulmonary embolectomy
office-based ; emergency room practice ; children ; undiagnosed heart disease ; HF
heart magnetic resonance imaging ; chelation choices ; patient compliance ; heart failure ; arrhythmias
ejection fraction ;EF ; pre-PD ; NYHA class IIIb ; ventricular dysfunction
cPCs ; early-outgrowth colony-forming units ;EO-cFUs ; circulating CD34 ; vEGFR2 ; CD133
Bax ; bcl-2 mRNA expression ; heart failure ; bcl-2/Bax
nitroxyl ; hno ; Angeli ; salt ; inotropic ; lusitropic ; vasodilator effects ; cAMP
anticoagulation ; rate control ; cardiovascular complications ;stroke ; cardiovascular death ; acute heart failure
clinical effects ; coût-effectiveness ; continuous-flow lVADs ; hm ; HeartWare ; bt ; DT
EF ; blinded core laboratory
skeletal muscle mass ; appendicular lean mass index
DASh ; mortality ; HF
Quality of life ; mortality
bp ; inhospital mortality
cardiovascular diseases ; heart failure ;HF
heart failure ; ventricular systolic dysfunction
CLCNKA polymorphism ; heart failure ; glomerular filtration rate ; RENASTUR
implants ; ambulatory patients ; HF
cardiac VEGF expression ; Akt ; endothelial NO synthase activation ; drug-untreated failing hearts
cultured cardiomyocytes ; jq1 ; drug abrogated ; phenylephrine-induced genes
ventricular contractile reserve
Gene expression profile ; Gene Expression Omnibus ; non-ischemic heart failure ; ischemic
cardiac insulin-resistance ; insulin-stimulated rates ; glycolysis ; glucose oxidation ; plasma membrane translocation ; glucose transporter
DASh ; sRD brachial ; central blood pressure ; radial arterial tonometry ; cardiovascular ; echocardiographic
Psychosocial Factors ; Exercise Adherence ; Heart Failure Patients ; Heart Failure ; HF-ACTION
coronary angiography ; systolic HF ; unclear etiology
arterial elastance ; end-systolic elastance ; ees ; ventricular-arterial coupling
rhythm control therapy ; antiarrhythmic drugs ; catheter ablation ; electrocardiographic device
angiotensin II ; angII ; hypoxia ; activators ; abnormal sCN5a mRNA splicing ; sCN5a
HF ; reduced ejection fraction ;HFrEF ; HF ; preserved ejection fraction ;HFpEF
extracorporeal life support ; bridging therapy ; acute ischemic right heart failure ; refractory cardiogenic shock ; reperfusion therapy
heart failure ; left ventricular ejection fraction ; fes ; exercise capacity ; emotional status ; endothelial function ; HFpEF
implantable cardiac arrhythmia devices ; noncardiovascular diagnoses ; implantable cardiac arrhythmia devices ; noncardiovascular drugs
intubation rates
raloxifene
hearts ; TTA ; tgtetMena mice ; wild-type littermates ; heart mass ; transgenic mice
hff ; respiratory gas
guideline-recommended drugs ; heart failure
fat ; lean mass ; fat loss ; catabolism ; adipose tissue
hearts ; fish lacking ; nucleolin ; chamber patterning ; functional deficits ; cardiac looping ; myocyte
black race in patients ; chronic HF ; modifiable risk factors ; exercise performance ; HF
adverse event rates ; acute myocardial infarction ; congestive heart failure
cardiomyocytes ; Hum-Retn mice ; doxorubicin ; hRetn ;human resistin ; mRNA
lVADs ; CF devices ; HeartMate II devices ; Thoratec Corp ; Pleasanton ; Calif ; hVAD devices ; HeartWare intl ; Framingham ; Mass
FM ; plasma NPs ; adiponectin
sympathetic tone ; parasympathetic tone ; heart rate ; metoprolol ; atropine
EH ; HFpEF ; HF ; hff therapy
HF ; immunoreactive NT-probNP ; c-terminally truncated fragments ; NT-probNP
beat-to-beat QT interval ; surface ECGs ; atrial pacing ; esmolol ; isoprenaline

power ; low-frequency/high-frequency ;LF ;HF ; CHF-INV ; sham-inv ; sham levels ; DNx
ventricular-arterial coupling ; ivabradine-tre
hospital quality improvement initiative
natriuretic peptide ;NT-probNP ; misdiagnosis ; heart failure ;HF
cardiac magnetic resonance ; hfEF ; biomarker ; hff
HF-ACtion ; left ventricular ejection fraction ; New York Heart Association ; HF
myocardial DD ; collagen deposition ; titin modification ; obese ; diabetic ZSF1 rats ; heart failure
cardiac tissue ; mice ; TAC- ; sham-operated ; jq1 ; vehicle ; BET inhibition suppresses a pathological cardiac gene expression programme
cox-proportional hazard models ; negative binomial regression models ; intervention ; survival ; utilization
Systolic blood pressure ; left ventricular ;LV ; hypertrophy ; AN ; AS ; ANS
conditional gene-targeted Hand2 mice ; pressure-overload-induced hypertrophy ; fibrosis ; ventricular dysfunction ; fetal gene program
NT-proBNP ; prescriptive 4-year survival ; ED ; acute HF
oxygen ;VO2max ; resting HR

frailty ; Health ABC Short Physical Performance Battery ; hABC Battery ; Gill index ; HF
epigenetic readers in cardiac biology ; manipulation of cardiac gene control ; chromatin-dependent signal transduction ; abrogate pathological gene expression ; HF progression
clinical prediction rule ; CAD ; angiography ; systolic HF
chronotropic response ; heart rate
hospital ; gastrointestinal bleeding ; ventricular tachycardia storm
catheter-based percutaneous revascularization ; angioplasty ; stenting
HF ; t2d ; ERC ; treadmill testing ;VO2max ; oxygen consumption ; Skm biopsies
HF ; QRs prolongation ; LVEF ; cRT ; reverse remodeling ; clinical benefit ; LV systolic dysfunction
RV support ; lVAD insertion ; cardiogenic shock ; myocardial infarction ; chronic decompensated heart failure

non-frail participants ; gr index ; HF
HF ; AMI
Chronic heart failure ;CHf ; multisystem disease ; anemia ; insulin resistance ; autonomic dysbalance ; cardiac cachexia
β-AR stimulation ; catecholamine infusions ; rats ; pde2 expression ; cAMP hydrolytic activity ; blunted cardiac β-AR responsiveness
chronic PAH ; hospitalized patients ; RV decompensation ; pharmacologic therapies
obese ZSF1 groups ; heart failure ; ejection fraction ; lung weight ; ventricular ejection fraction ; left ventricular DD
Xanthine oxidase ;XO ; rat ; ventricular ;LV ; volume overload ;VO ; mitral regurgitation ; aortocaval fistula
free-breathing pulse sequence ; myocardial t1 changes ; swine model ; tachycardia-induced heart failure
PF cohort ; New York Heart Association
comanagement ; patients
patients ; high-volume physicians ; low-volume physicians
Western austral ; administrative health ; HF
conditions
eds ; heart failure
nursing-sensitive outcome
miRNAs ; noncoding RNAs ; expression ; target genes ; binding ; messenger RNA ; degradation ; translational repression
HFpEF ; ivabradine 5 mg ; placebo
Cardiac c-Kit ; cardiac explant-derived cells
NPs ; pulmonary embolism ; diabetes
pathophysiology ; HF ; medical management
empirically derived composite quality measure ; heart failure ;HF ; acute myocardial infarction ;AMI ; pneumonia ; pna
mortality ; healthcare utilization effects ; care management ; telehealth ; congestive heart failure ; chronic obstructive pulmonary disease ; diabetes mellitus
inhibitor Jq1 ; BETs ; chromatin ; suppression ; downstream signalling ; RNA polymerase II ;Pol II
catheter ablation ; atrial fibrillation ;AF ; heart failure ; preserved ejection fraction ; hfEF
heart failure ; preserved ejection fraction ;HFpEF
cox proportional hazards regression ; implantation ; acute coronary syndromes ; coronary interventions
cyclic adenosine monophosphate ; cAMP ; cyclic guanosine monophosphate ; cgmp ; failing hearts
RA ; methotrexate ; tNF antagonist ; non-biological disease modifying antirheumatic drug ;nbDMARD
intestinal dysfunction ; disturbed intestinal barrier ; chronic inflammatory state ; catabolic/anabolic imbalance ; cardiac cachexia
ischemic-hypertensive cardiomyiopathy ; angina ; inducible myocardial ischemia ; coronary arteries
sphingosine-1-phosphate receptor ; s1PR ; β1-adrenergic receptor ;β1AR ; g-protein-coupled receptors ; heart
septal correlated ; PCWP
inappropriate therapy ; atrial fibrillation
Bradycardia induced ; intravenous metoprolol ; cardiac sympathetic tone ; CHF-INv rabbits ; sham-INv ; CHF-DNx
Nordic walking ; cardiac rehabilitation ; functional capacity ; patients ; moderate to severe heart failure
cPG-recommended pharmacological treatment ; device consideration ; self-care education ; left ventricular
grLS ; LVEF ; sa ; CV ; prognostic benefit ; echocardiographic systolic parameters ; AF
ERC ; DAPc protein ; sarcomeric microstructure ; Skm growth ; myofibre regeneration
signalling cascades ; microRNAs ; bHLh transcription factor Hand2 ; postnatal mammalian myocardium ; embryonic gene programs in heart failure
rad Q66p ; inhibitory actions ; rad ; cav1.2 ; cav1.3 ; l-type channel isoforms ; heart
EF ; LCx model ; LAD ; stenting ; infarcted left ventricle ; LCx ; LAD
EH ; LV ; ml end-diastolic volume ; ml
mva ; surgical ring implantation ; leaflet motion ; angle-to-edge anastomosis
hART ; New York Heart Association ;NYHA ; HF ; self-management counseling ; death ; HF
cardiac function ; echocardiography ; diastolic dysfunction ; ejection fraction
BET family bromodomain proteins ;BETs ; acetyl-lysine reader proteins ; HF
transfusions ; iron ; erythropoiesis-stimulating agents ; anemia ; congestive heart failure ; coronary heart disease
Grading of recommendations
HF
implantation ; right heart circulatory failure
influx ; l-type voltage-gated ca ; figure ; ventricular action potentials ; excitation-contraction ;EC ; coupling ; myocardium
ivabradine ; ventricular filling ; heart failure ; preserved ejection fraction ;HFpEF
aldosterone antagonism ; heart failure ; aldosterone ; neurohormone ; electrolytes
bNP ; glomerular filtration rate ; hypertension ; transmitral E-wave ; diastolic mitral annular velocity
AT1 receptors ; neprilysin blocks renin-angiotensin-aldosteron ; RAS ; vasodilatory ; diuretic peptides
β-blockade ; disease progression ; cAMP-dependent protein kinase ; pKA ; β-adrenergic receptor
erythropoiesis-stimulating agent therapy
black race ; mortality/hospitalization ;hazard ratio ; cardiovascular mortality ;HF
figure ; chronic myocardial ischemia ; stent coated ; polytetrafluoroethylene tube
clinical ; genetic ; CHF predictive model ; figure
multivariable logistic analysis ; AT ; peak oxygen uptake ; metabolic exercise ; cardiac
heart failure ;HF ; tumor necrosis factor ;TNf ; tNF antagonists ; HF
Centers for Medicare and Medicaid services ; cMS ; hospital quality of care outcomes ; mortality ; readmission
cox proportional hazard models ; temps-dependent covariates
techniques regression analysis ; severe CAD ; diameter stenosis ; left main ; 3-vessel CAD ; angle descending arter
signal transduction cascade ; transcription factors ; cardiomyocytes ; transcription factors ; epigenetic changes ; chromatin structure
hypertensive HFPEF ; sodium-restricted DASH ; ventricular diastolic function ; arterial elastance ; ventricular-arterial coupling
annular size reduction ; surgery ; diastolic mitral valve tethering ; anterior leaflet opening ; papillary muscles ; ventricular dilatation
aldactone Evaluation Study ; chronic advanced heart failure ; aldosterone antagonist ; spironolactone
incidence ; mortality outcomes ; heart failure ; acute myocardial infarction
CHF ; hCT ; polymorphisms ; anthracycline metabolism ; iron homeostasis ; anti-oxidant defence ; myocardial remodelling
medication
pathophysiological origin
lVAD surgery
creatinine ;hazard ratio ; dL
glomerular filtration
scientific literature ; clinical studies ; HM II ; HeartWare patients ; economic evaluations ;HM II
implantance ; dopamine ; low-dose nesiritide ; renal
HR variability/turbulence
implantation ; lVAD therapy ; implantation eligibility status ; device ; bt ; DT
radial artery tonometry variables
magnetically levitated centrifugal-flow chronic lVAS
signalling ; scaffold protein ; kinases ; sequential phosphorylation ; effector molecules
Medicare coverage ; breast cancer ; chemotherapy ; sEER-Medicare ; Texas Cancer Registry-Medicare
ejection fraction ; natriuretic peptide ; heart failure ; inhospital outcomes ; guideline-Heart Failure Registry
cardiomyocytes ; pde2 activity ; cgMP synthesis ; nitric oxide ; pde2 inhibition ; β-AR responsiveness
l-dKO mice ; cardiac IRS1 ; IRS2 proteins ; heart failure ; impaired cardiac energy metabolism ; active ; protein kinase
ECs ; HDL ; phosphorylation ; eNOS-Ser ; eNOS-Thr ; PKc-βII-Ser
pasp ; walking distance
rCTs ; sts ; HH ; HM ; t
mouse ventricular myocytes ; sarcomere
administrative databases ; province of Alberta
animals ; heart failure
cRT ; temps to death ; HF hospitalization ;hazard ratio ; LVEF
adrenergic receptor ; sphingosine-1-phosphate receptor ; reciprocal downregulation ; cardiac hypertrophic response ; heart failure ; s1PR1 cardiac gene therapy
RR ; heart failure ; bisphophonates ; crude RR
Medicare fee-for-service beneficiaries ; Centers for Medicare ; Medicaid Services ; propensity-score
physician adherence ; guideline recommendations in heart failure
doxorubicin-induced heart failure ; rats ; hemodynamic perturbations ; mitochondrial dysfunction ; ultrastructural changes ; antitumor activity
kccq ; New York Heart Association class ; HFpEF ; HF ; EF
Rhythm control therapy ; af ; atrial structure ; rhythm ; delayed rhythm control
acute heart failure ; renal dysfunction ; low-dose dopamine ; nesiritide ; decongestion ; renal function
HF ; body composition ; skinfold thickness ; dual-energy X-ray absorptiometry ; echocardiography ; blood testing
heart failure
aCP ; restrictive red blood cell transfusion strategy ;trigger hemoglobin threshold ; hemoglobin levels ; coronary heart disease
hospitals ; conditions ; acute myocardial infarction ; pneumonia
implanted left-right interatrial shunt ; haemodynamic outcomes ; heart failure
ventricular-pulmonary arterial coupling ;pulmonary vascular resistance
ventricular assist devices ; lVADs ; chronic end-stage heart failure ;bridge to transplantation ; bt ; transplant-ineligible patients ; destination therapy
Caloric restriction ; Aerobic Exercise Training ; Peak oxygen Consumption ; Quality of Life ; Heart Failure ; Preserved ejection Fraction
carvedilol ; metoprolol ; implantable implantable cardioverter-defibrillator therapy ; MADit-cRT ; multicenter Automatic Defibrillator implantation ; Cardiac resynchronization Therapy
glucocorticoids ; HF
HR ; ivabradine group ; TAC
carvedilol ; inappropriate therapy
chm ; adjunctive treatment ; dCM ; heart failure
testosterone supplementation ; exercise rehabilitation
VO2 ; change ; lean body mass ; change ; thigh muscle ;intermuscular fat ratio
guidelines-Heart Failure ; HF ;EF ;EF
économique Analysis ; Patient Management Interventions in Heart Failure Cost-Effectiveness Model ; coût-effectiveness ; disease management programs in heart failure
HFPSI ; risk of death ; medical hospitalization ; HF clinic outpatients ; HF resources
cardiac insulin-resistance ; mitochondrial oxidative metabolism ; metabolic changes ; cardiac hypertrophy ; energy deficit ; hypertrophy ; heart failure
cox model ; age ; sex ; PASp ; figure
pathophysiology ; heart failure ; preserved ejection fraction ; hff ; myocardial extracellular matrix accumulation
annular size reduction ; surgery ; diastolic mitral valve tethering ; anterior leaflet opening ; papillary muscles ; left ventricular ;LV
breathing control ; cardiac arrest ; ventricular fibrillation ;PVf ; implanted cardioverter-defibrillator device
rad ; rem ; rem2 ; rad ; Gem ;Kir ; monomeric G proteins ; ventricular action ; EC coupling gain ; inhibit cardiac l-type channel activity
acetylcholinesterase inhibitor pyridostigmine ; sympathovagal balance ; cardiac remodeling ; HF
cardiac sympathetic activity ; i-meta-iodobenzylguanidine ; i-MIBG ; β-blocker
Swedish web-system ; evidence-based care in Heart disease ; Recommended Therapies registry ; caBG
LVEF ; clinical composite response ; reverse remodeling parameters
brain natriuretic peptide ; bNP ; bNP ; bNP
coprimary end points ; cumulative urine volume ; decongestion end point ; serum cystatin C
tAPse ; longitudinal RV fiber shortening ; PASp ;force generated ; RV ; in vivo RV length-force
pde superfamily ; pde2 ; cgmp ; cAMP hydrolysis ; negative cross talk ; cgmp ; cAMP signaling
proBNP ; midregional proANp ;MR-proANp ; adiponectin ; CHF ; bmi ; FM
re-hospitalization
protectionive effects ; mitochondrial-targeted antioxidant ; protective peptides ; Szeto-Schiller ;SS ; cardiac function ; proteomic remodeling ; signaling pathways
cardiac arrest ; cardiopulmonary resuscitation ; cPR ; posterior wall infarction ; cardiac centre
hyperkalemia ; mineralocorticoid receptor antagonists ; race ; mineralocorticoid receptor antagonists ; heart failure ;HF
aCP ; erythropoiesis-stimulating agents ; anemia ; congestive heart failure ; coronary heart disease
diabetes ; saxagliptin ; sitagliptin ; pioglitazone ; second-generation sulfonylureas ; long-acting insulin
uPR ; sCN5a ; ventricular systolic HF ; implanted pluripotent stem cell-derived cardiomyocytes ;hiPSc-CMs
ambulatory patients ; heart failure ;HF ; ejection fraction ;rEF ; renin-angiotensin system ; RAS ; β-blockers
cochrane Effective Practice ; organisation of Care Taxonomy
coPD ; CHF ; cRF ; ICC
heart failure ; left ventricular ejection fraction
implantable cardioverter-defibrillator deactivation ; implant
heart failure ; poor myocardial function ; children ; dilated ; ventricles
implantable cardioverter-defibrillator deactivation ; implantable implantable cardioverter-defibrillator deactivation ; implantable implantable cardioverter-defibrillator shocks
global left ventricular longitudinal systolic strain ; gLS ; left ventricular mechanics ; adverse cardiovascular ;CV ; atrial fibrillation ;AF
mouse rad ; murine equivalent ; human rad Q66p ; l-type currents ; cav1.2 ; cav1.3 ; wild-type Rad
patient ; MI ; hf
Medicare ; patients ; acute care hospital ; HF ; AMI ; pna
cardiovascular events ; baseline sST2 status ; hz ; ml
ctnt ; NT-probNP ; aRIC HF model ; aucs ; continuous NRIs
HF ; HF ; EF ; HF ; HF ; mis ; prevention strategies
incubation ; EC ; HDL ; NYHA-IIIb ; phosphorylation ; eNOS-Ser ; phosphorylation ; eNOS-Thr ; HDL
carvedilol ; Willebrand factor ; metoprolol
mouse heart failure ;HF ; hypertensive heart disease ; hHD ; pathophysiology ; therapeutic targets ; hHD
sarcoplasmic reticular ;SR ; ca(2+)-uptake ; protein ; SR ; ca(2+)-pump ; phospholamban ; infarcted hearts ; metoprolol
temps ; tug ; chronic obstructive pulmonary disease ;COPD ; chronic heart failure ;CHf ; chronic renal failure ;CRf
implantable testosterone supplementation ; chronic heart failure ;CHf ; low testosterone status
HF ; long-term mortality ; LVEF
gLS ; left ventricular ejection fraction ;LVEF ; systolic mitral annulus velocity ; sa
heart failure ;HF ; plasma ; natriuretic peptide ; bNP ; ejection fraction ; HF ; sex
implanted monitoring devices ; medical support ; structured telephone support ; sts ; human-to-human contact ; h ; h
temps-dependent cox regression analysis ; beta-blockers ; beta-blockers ; inappropriate therapy ; antitachycardia pacing ; aTP
ethically complex situations ; pediatrics ; families ; religious beliefs ; life-sustaining treatment
patient preferences ; priorities ; guideline-recommended medications
coût ; rhythm-control
ventricular ejection fraction ; figure
fit ; unfit ; cRF distribution ; hazard ratios ; unfit ; obese men
cRT ; control group ; hazard ratio
HFPSI ; blood urea nitrogen ; b-type natriuretic peptide ; New York Heart Association class ; diabetes ; atrial fibrillation/flutter
Medicare Patient Safety Monitoring System ;MPSMS ; adverse event rates ; patients hospitalized ; acute myocardial infarction ; congestive heart failure ; pneumonia
CD34 ;vegFR2 ; cells ; functional capacity ; figure
practice-level variation ; guideline-recommended treatment ; heart failure ; reduced ejection fraction
figure-fatality rate ; patients ; concurrent HF ; HF
CHF ; anthracycline exposure ; stem cell source ; autologous
tension ; figure ; kcl-KI ; titin ; extracellular matrix
reversibility ; heart failure ; myocardial infarction ;MI ; β-adrenoceptor blockade ; infarcted rats ; metoprolol
aerobic ; resistance training ; gain ; exercise capacity ; muscle strength ; quality of life ; cardiac ;NT-probNP ; inflammatory ; hsCRp
hospital performance ; all-cause readmission ; aCR ; Potential Preventable Readmission ; pPR ; Centers for Medicare ; Medicaid ; cMS
congestive heart failure

secretion ; arginine vasopressin ; aVP ; physiologic processes ; CHF ; aVP ; vasopressin receptor antagonist therapy ; CHF
angiotensin-converting enzyme inhibitors ;angiotensin receptor blockers ; β-blockers ; heart failure
implantable defibrillators ; circulatory support ; transplantation ; heart failure ; therapies
hypertension diet ;DASh ; sRD ; ventricular diastolic function ; arterial elastance ; ventricular-arterial coupling ; hypertensive HFPEF
ventricular pacing ; Bax ; bcl-2 ; Caspase-3 ; RTq-PCr ; interventricular septum biopsies ; beagle dogs ; heart failure
rats ; hearts ; caspase-3 activity ; phosphocreatine ; adenine nucleotides ; cytochrome c ; bcl2 ; Bax ; caspase 3 expression
metoprolol ; carvedilol ; sympathetic activity
acute HF trials ; RELAx-aHF ; ASTRONAUT ; PRONTO
Hospitalized HF ; international Classification of Diseases ; Clinical Modification codes ; principal discharge diagnosis
Pulmonary capillary wedge pressure ; hg ; hg ; pulmonary arterial ; pulmonary resistance
rad Q65p ; gating movement ; rad ; wild-type Rad ; Q65p ; implantation ; l-type channel inhibition ; RGK proteins
heart failure ; global proteomics changes ; actin cytoskeleton pathways ; mitochondrial ; metabolic
aortic insufficiency ;AI ; mechanical circulatory support ; continuous flow ;CF ; left ventricular assist devices ; lVADs ; pulsatile devices
pyridostigmine ; coronary artery ligation ; cardiac vagal ; sympathetic tone ; cardiac remodeling ; ventricular dysfunction ; HF
discharge
implantation ; heart failure ; implantation
heart failure discharges ; University of Connecticut health Center
implants ; New York Heart Association ;NYHA ; class II Heart Failure ; eplerenone ; placebo ; standard Heart Failure Medicines ;EMPHASIS-HF
echocardiograms ; left ventricular base ; midpapillary ; apex ; IVc occlusion ; biVP ; twist ; apical ; basal rotations ; CS ; synchrony
drugs ; RAas ; direct renin inhibitors ; neutral endopeptidase inhibitors ; vasopeptidase inhibitors ; angiotensin receptor blockers
acute heart failure ;HF ; pharmacologic studies ; calcium-sensitizing agents ; endothelin ; vasopressin ; adenosine
HF induced ; mice ; phenylephrine ; haemodynamic stress ; surgical method of transverse aortic constriction ;TAC ; jq1 ; cardiac hypertrophy
Muscle aerobic capacity ; postexercise phosphocreatine resynthesis ; Fontan
i-MIBG cardiac washout ; carvedilol ; metoprolol treatment ; β2-adrenergic receptor haplotype
acute myocardial infarction ; AMI ; incidence ; heart failure ;HF ; complicating AMI
h-dKO mice ; ventricular mass ; cardiac apoptosis ; fibrosis
bottleneck stent ; proximal left anterior descending ;LAD ; proximal circumflex artery ;LCx ; LCx ; LAD
hospitalized heart failure ; hHF ; dipeptidyl peptidase-4 ; dPP-4 ; antihyperglycemic agents
quality improvement database ; multivariable cox modeling ; Heart Failure Patient Severity Index ;HFPSI ; University of Michigan HF clinic
pde2 overexpression ; healthy cardiomyocytes ; cAMP ; l-type ca2 ; inotropic effect ; acute β-AR stimulation ; basal contractility
inappropriate ATP ; shock therapy
Cardiac resynchronization therapy ; cRT ; dialysis-dependent patients ; heart failure ;HF
cardiorespiratory fitness ;CRf ; body mass index ; heart failure ;HF ; cardiovascular risk factors ; HF mortality ; fit ; unfit men
eplerenone ; hyperkalemia ; renal function ; EMPHASIS-HF ; eplerenone in Mild Patients Hospitalization ; survIval Study in Heart Failure
cardiac patients ; acute myocardial infarction ;AMI ; congestive heart failure ;CHf ; left ventricular ;LV
ventricular cardiomyocytes ; chronic insulin exposure ; iRS1 ; iRS2 proteins ; insulin action ; cardiac dysfunction ; insulin resistance ; type 2 diabetes
ventricular midpapillary ; atrioventricular delay ; avd ; interventricular delay ;VVd ; STE ; regional circumferential strain ;CS ; radial strain ;RS
New York Heart Association ;NYHA ; HF ; ejection fractions ; chronic stable guideline-directed medical therapy ;GDMT
LBBB ; QRs ; hazard ratio
dyssynchronous HF ; myofiber shortening velocity ; septum ; myofiber shortening ; stretch rate ; lateral wall
label-free shotgun proteomics ; global proteomics changes ; transverse aortic constriction ; TAC ; heart failure ; signaling pathway
CHF ; c-Kit ; transforming growth factor-β ; tGF-β ; epithelial ; mesenchymal transition markers ; pluripotency markers
pka ; regulatory ;RIIα ; catalytic ; cα ; phosphorylation ; HF
hf ; left ventricular ejection fraction ; HFpEF ; left ventricular ejection fraction ; RAS- ; β-blocker ; index HF
g-protein-coupled receptors ; reciprocal regulation ; mouse hearts ; chronic β-adrenergic receptor stimulation ; rat ; postischemic heart failure
concentric remodeling ;CR ; concentric hypertrophy ;CH ; left ventricular ;LV ; implanting in heart failure ; preserved ejection fraction ;HFpEF ; eccentric hypertrophy ;EH
weight ; diet group ; figure
risk ; RV dysfunction ;hazard ratio ; confidence interval ; CI ; cachexia
resting HR
TGF-β inhibition ; c-Kit+ cell ; implantation ; cardiac progenitor function ; cell expansion
NT-proBNP ; inflammatory biomarkers ; hsCRp ; IL ; hsCRp
BETs ; neurohormonally induced heart disease ; jq1 ; phenylephrine-mediated hypertrophy ; cardiomyocytes ; pathological gene induction
BAT ; physique ; exercise capacity ; pro-brain natriuretic peptide ; burden ; heart failure ; GDMT-treated NYHA functional class III HF
activation ; PKc-βII ; malondialdehyde bound ; HDL ; NYHA-IIIb
MLHF
nonpace ; non-DNx ; sham-Innervated ; sham-inv ; nonpace DNx ; h-DNx ; pace non-DNx ; hf- inv ; pace ; DNx ; hf-DNx
hABC Battery score ; HF risk ; health ABC HF Model ; hz ; hz ; SD
age ; sex ; ejection fraction ; frail ; biological phenotype ; risk of death
hemoglobin ; hgb ; HRQoL ; training-induced changes ; HRQoL ; patients in Heart Failure ; HF-ACTION
atrial Fibrillation ; congestive Heart Failure trial ; health care expenditures ; patients ; rhythm ; rate-control treatment
heart failure ; myocardial ischaemia ; bradyarrhythmias ; valvular regurgitation ; pulmonary embolism ; renal dysfunction
calcineurin ; Nfat signalling ; miR-25 expression ; helix-loop-helix ; bHLh ; Hand ; diseased human ; mouse
PSSS ; btes ; btes
NT-probNP
r-r interval oscillations ; HR variability ; short-term fractal scaling exponent
diastolic filling formalism ; relaxation/viscoelastic ; passive/stiffness ; doppler mitral inflow velocity ; e-wave
heart failure ;HF ; ventricular tachycardia ; HF ; HF ; VT ; hnm
grLS ; cox model ; chronic heart failure ; hypertension ; diabetes ; prior stroke score ; glomerular filtration rate ; LVEF ; adverse CV
ventricular assist device support ; ECmo ; extracorporeal membrane oxygenation membrane support ; ECmo ; VAD
ischemic events ; ies ; ischemic cardiomyopathy ;IC ; cardiac resynchronization therapy ; defibrillator ; cRT-D
coût-effectiveness ; heart failure disease management ; implanting ; evidence-based treatments
résistancein in heart failure ; humanized mouse ; murine resistin ; transgenic ; human Retn gene ; hum-retn mice ; basal ; inflammation-stimulated resistin
angiotensin-converting enzyme inhibitors ;angiotensin receptors blockers ; β-blockers ; devices
ttttMena mice ; cardiac injury ; ejection fraction ; fractional ; heart dilatation ; hypertrophy ; transverse aortic constriction
resynchronization-Defibrillation ; Ambulatory Heart Failure Trial ; implantable cardioverter defibrillator-CRT ; mortality ; heart failure
heart failure patients ; Italy ; confirmatory factor analysis ; cfa ; SCHFI ;Self-Care Maintenance ; Self-Care Management ; Self-Care Confidence
mt ; NYha class ; HFpEF ; hFrEF ; therapy ; HFpEF ; HFpEF
renal dysfunction ; chronic obstructive pulmonary disease ; diabetes ; peripheral vascular disease ; left ventricular ejection fraction ; iCD shocks ; mortality ; ischemic cardiomyopathy
Raf-MEK1/2-ERk1/2 scaffold proteins ; adaptive ; maladaptive cardiac remodelling
CHF ; implante ; SD testosterone ; testosterone
functional MS ; LV dilatation ; heart failure ; HF ; LV ; functional MS ; HF ; MR ; degenerative mitral valve
associations ; New York Heart Association class ; kccq ; symptom ; HF ; HFpEF
angiotensin converting enzyme inhibitor ; angiotensin-receptor blockers ; β-blockers ; heart failure
c57BL ; ANG II infusion ; uninephrectomy ; ang II infusion ; salt loading ; ang II infusion ; uninephrectomy
transmissionral blood flow ; tissue ; doppler early diastolic mitral ; annulus velocity ; pulmonary capillary wedge pressure ;PCWP ; decompensated systolic heart failure ;HF
LV ; ejection fraction ; LV strain ; strain rate at systole ; diastolic indices ; LV strain rate ; diastole ; early transmitral flow ; sinus rhythm
peak VO2
age- ; sex-adjusted risk ; HF
AMI patient ; hospital
Mass spectrometry ; n- ; c-terminally processed forms ; circulating NT-proBNP ; physiological proteolysis ; leu ; figure
sex-specific model ; ctnt ; NT-probNP ; laboratory report ; ctnt ; NT-probNP
HFpEF patients ; New York Heart Association class II ; figure ejection fraction
depressed left ventricular ;LV ; pressure ; pressure ; ejection fraction ; fractional shortening ; cardiac output ; LV end-diastolic pressure ; mis ; metoprolol
baroreflex Activation Therapy ; Heart Failure ; Reduced ejection Fraction ; clinical trial ; carotid baroreflex activation therapy ;BAT ; advanced heart failure ;HF
enrollment
HF ; HF ; raised blood glucose levels ; obesity ; tobacco ; aging ; systemic hypertension ;SH ; rheumatic fever ; Chagas' disease ; cd
hazard ratios ; cRF
kccq ; HFpEF
egFR group ; egFR group ; uncontrolled hypertension ; diuretics ; temps ; ESRD
myocardial phosphodiesterase-2 ; pde2 ; heart failure ;HF ; pde2-mediated effects ; beta-adrenergic receptor ;β-AR ; cardiomyocytes
heart failure ; cardiac resynchronization therapy ; defibrillator ; implantable cardioverter-defibrillator device ; carvedilol ; inappropriate ATP ; shock therapy ; metoprolol
epicatechin-rich cocoa ; Skm mitochondrial structure ; Ramirez-Sanchez ; ciaraldi ; perkins ; Murphy ; naviaux ; Hogan ; ceballos ; Maisel
risk ; urgent readmission
Mena overexpression ; TTA ; tgtttMena mice ; TAC surgery ; cardiac hypertrophy ; TTA ; tgtetMena
echocardiography ; reduction ; LV end-diastolic volume ; disappearance ; MR ; mitral valve opening ; mVA ; pression gradient ; hg
institution of PD ; diuretic refractory severe-end-stage HF
ATP production rates ; mitochondrial oxidation ; glucose ; lactate ; fatty acids ; myocardial glycolysis
eplerenone ; potassium ; potassium ; hyperkalemia ; medication
implant aged ; New York Heart Association class III heart failure ; HF ; ventricular ejection fraction ; permanent periodic breathing ;PB
implantation ; bottleneck stent ; proximal LAD ; LCx ; reversible myocardial ischemia ;open stent ; ischemic heart failure ; stent
potassium ; spironolactone ; AAs ; race
obese participants ; hff ; hff
proangiogenic effects ; b act via activation ; VEGF pathway ; adenoviral vector ; decoy VEGF receptor ; ad-flk ; control adenovirus ; ad-c
surgical treatment ; post-LVAD AI ; aortic valve oversewing ; leaflet repair ; bioprosthetic aortic valve replacement
exercise-induced pulmonary artery systolic pressure ;PASp ; stress ; doppler echocardiography ; right ventricular contractile reserve ; pulmonary hypertension ; right heart failure
MEDLINE ; EMBAse ; HEalthSTAR ; cINAHL ; cochrane Library ; Campbell Collaboration ; Joanna Briggs Institute Evidence Based Practice
veterans ; VA healthcare systems ; systolic heart failure ; β-blocker ; angiotensin converting enzyme inhibitor ; angiotensin-receptor blocker
heart failure ; neuro-hormonal system ; angiotensin converting enzyme inhibitors ;angiotensin receptor blockers ; angiotensin converting enzyme inhibitors intolerance ; beta receptor blockers ; mineralocorticoid receptor antagonists
open chest model ; twist ; RS synchrony ; CS ; CO
TAPse ; PASp ; tAPse-to-PASp ratio ;TAPSe ;PASp ; cox regression ; Kaplan-meier
cPET ; CHF
Human heart failure ;HF ; mRNA splicing ; v ; voltage-gated cardiac na+ channel ; sCN5a ; truncated ; nonfunctional channels ; endoplasmic reticulum
paediatric heart failure ; myocarditis ; dilated cardiomyopathy ; heart failure ; anthracycline ; childhood malignant disease
économique Analysis ; Patient Management Interventions in Heart Failure Cost-Effectiveness Model
natriuretic peptides ;NPs ; acute heart failure ; Emergency Department ;ED ; acute dyspnea
peak oxygen consumption ;peak VO2 ; ven ; vco2 slope ; exercise oscillatory ventilation ; eOV ; pressure ; end-tidal CO2 ;PETco2 ; cardiopulmonary exercise testing
france ; bisphosphonates ; raloxifene
hypertension ; LV dilatation ; LV dysfunction ; MR ; MS
hyponatremia ; Japan ; congestive heart failure patients ; optimal diuretic therapy ; serum sodium levels ; systo
longitudinal strain ; left ventricle ; echocardiographic measurements ; patients ; baseline echocardiography ; cRT ; echocardiograms
platelet-activating factor ;PAf ; metabolic enzymes ; patients ; heart failure
acute care surgery ;ACs ; oHT ; transplantation ; medical therapy ; intravenous inotropes ; ventricular assist devices ;VADs
HFpEF ; ivabradine ; ventricular filling pressure ; exercise
renin-angiotensin-aldosterone system ;raas ; hfrEF ; angiotensin-converting enzyme inhibitors ; angiotensin receptor blockers ; aldosterone blockade
lVET ; unfavorable outcome
correction ; heart rate ; blood pressure ; renal function ; spironolactone ; RAS blockers ; β-blockers
cardiac performance ; β-adrenoceptor blockade ; heart failure
angiotensin-converting enzyme inhibitors ;angiotensin receptor blockers therapy ; β-blockers therapy
congestive heart failure ; mitochondrial damage ; TAC ; mitochondrial proteome changes ; mitochondrial ; nonmitochondrial protein
myofibrillar ca(2+)-stimulated ATPase activity ; mRNA levels ; SR ca(2+)-pump ; phospholamban ; α-myosin heavy chain
HDL ;healthy ; CHF-NYHA-III ;HDL ;NYHA-III ; ET ; CHF-NYHA-II ;HDL ;NYHA-II
inesthetized dogs ; coronary microembolization-induced HF ; cXL ; ventricular end-diastolic pressure ; myocardial oxygen consumption ; ejection fraction ; ventricular power index
md ; md ; md95%
baseline ; heart failure ; administration of contrast agent
HF ; idiopathic dilated cardiomyopathy ; c'd ; ischemic ; SH ; valvular ; alcohol
ST2 ; functional capacity ; long-term clinical outcomes ; ambulatory patients ; HF ; Heart Failure ; controlled Trial Investigating Outcomes of Exercise Training ; HF-ACTION ; multicenter ; exercise training in HF
cardiopulmonary exercise testing ; exercise rehabilitation ; patients ; chronic heart failure ;CHf ; CardioPulmonary Exercise Testing ; cPET ; exercise rehabilitation
ischemic HF pathogenesis ; NYHA functional class IV ; glomerular filtration rate ; heart rate ; hypertension ; diabetes mellitus ; myocardial infarction
HF-ACtion ; exercise training ; HF ; ventricular ejection fractions ; HRQoL ; Kansas City Cardiomyopathy Questionnaire ; kccq
cRT ; systolic dysfunction ; resynchronization reVErses remodeling ; Systolic left v entricular dysfunction ; reVERSe ; left ventricular ;LV ; ejection fraction ;LVEF
glomerular filtration rate ; egFR ; age ; diabetes ; cholesterol ; lDL-cholesterol ; CLCNKA GG
echocardiography ; LV end-diastolic dimension ; LV end-diastolic pressure ;wall stress ; lung weight ; aCF
angle ; aUC
spironolactone ; risk of hospitalization
Rate-control patients ; cardiac procedures ; coût ; antiarrhythmic drugs
diabetes mellitus ; cardiomyopathy ; β-blocker ; angiotensin-converting enzyme inhibitor ; angiotensin II receptor blocker
eplerenone Post myocardial infarction Heart failure Efficacy ; SUrvival Study ; eheSUS ; post-myocardial infarction patients ; heart failure ; mortality ; aldosterone antagonist eplerenone
implantable cardioverter-defibrillator therapy ; MADit-cRT ; multicenter Automatic Defibrillator implantation ; Cardiac resynchronization Therapy
heart failure-related mortality ; sudden death
DASh ; sRD ; 24-hour brachial systolic pressure ; hg ; central end-systolic pressure ; hg
HF ; obese ; body mass index ; ; black ethnicity ; idiopathic-dilated cardiomyopathy
mortality ; HF ; LVEF
ventricular ejection fraction ; World health Organization ; idiopathic dilated cardiomyopathy ; negative coronary angiography
european Society of Cardiology guidelines ; hff ; heart failure ; LV ejection fraction ; non-dilated left ventricle ; diastolic dysfunction ; inimpaired LV relaxation ; LV diastolic stiffness ; LV filling pressures
active ; β1ARs ; s1PR1s ; myocyte ; action ; cAMP production ; direct interaction ; receptors ; regulatory involvement ; g-protein-coupled receptor kinase-2
PAf-cPT ; PAf ; lyso-PAf-AT ; PAf-AH ; lp-PLA
heart failure ;mean ejection fraction ; cardiac rehabilitation care ; Nordic walking
dRS-stratified hazard ratios ; sitagliptin ; pioglitazone ; sitagliptin ; sulfonylureas ; sitagliptin ; insulin
skeletal muscle mass ; t-score ; figure ; sarcopenic range muscle
testosterone group ; peak oxygen uptake ; Beck depression inventory ; leg strength ; Medical Outcomes ; short-Form quality of life
RAS- ; β-blocker uptitrations ; hf ; hf ; hf ; hf ; hf
patients enrolled in Heart Failure ; controlled Trial Investigating Outcomes ; Exercise Training ;HF-ACTION ; social support ; barriers to exercise ; social support score ; pSS ; barriers to exercise score ; btes
ST2 ; cardiovascular death ; HF hospitalization ;hazard ratio ; mortality ; hazard ratios
heart association ; cardiopulmonary exercise testing ; lean mass quantification ; dual x-ray absorptiometry ; dXA ; calf muscle ; magnetic resonance spectroscopy
placebo ; dopamine ; low-dose nesiritide ; diuretic therapy ; renal dysfunction
cRT ; New York Heart Association class III ; IV heart failure ; left ventricular ejection fraction ; QRs duration ; echocardiographic evidence ; left ventricular dyssynchrony
ventricular ;LV ; HF ; right-sided cardiac catheterization ; transthoracic echocardiography ; transmitral flow velocities ; mitral annulus velocities ; diastole
acute coronary syndromes
HF ; lyso-paf-AT ; PAf-cPT ; PAf ; PAf-AH ; lp-PLA2
medical therapy ; sternotomy ; aortic valve procedures ; bioprosthetic valve replacement ; dacron patch closure ; aortic valve repairs ; transcatheter aortic valve ; aortic valve replacement
plasma N-terminal pro-B-type natriuretic peptide ;NT-proBNP ; long-term ; patients ; acute heart failure ; HF ; emergency department ;ED
cardiac troponin T ; ctnt ; biomarkers ; incident HF ; HF ; Atherosclerosis Risk in Communities ;ARIc
figure ; h ; figure ; fat-free
men ; figure ; figure ; body mass index ; figure
reverse remodeling ; ejection fraction ; mortality ; HF ; dialysis
EH ; LV contractility ; ch ; LVEF ; figure ; systolic blood pressure ; end-systolic volume ; hg
echocardiography ; ml ; end-diastolic volume index ; ml ; ejection fraction ; mild MR ; mitral valve opening ; ms ; mva ; pression gradient ; hg
double-blind ; placebo-controlled clinical trial ; renal Optimization Strategies Evaluation ;ROSe ; acute heart failure ; renal dysfunction ; glomerular filtration
BETs ; chromatin-mediated signal transduction ; Pol II ; co-activating transcription factor networks ; HF pathogenesis ; nuclear factor of activated T cells ; naFAT ; nuclear factor-κb ; NF-κb ; transcription factor
mortality ; hospitalization ; exercise tolerance ; quality of life ; cardiovascular events ; myocardial infarction ; congestive heart failure ; arrhythmia ; cardiac death ; hypertension ; venous thrombolic events ; ischemic cerebrovascular events
all-cause ; cardiovascular mortality
EO-cFUs ; diabetes ; EO-cFU ; diabetes ; EO-cFU ; diabetes
immunoblotting ; radioenzymatic- ; fluorescence resonance energy transfer-based assays ; video edge detection ; epifluorescence microscopy ; ca2 ; myocardial tissues ; cardiomyocytes ; HF
eAST ; atrial fibrillation ; Stroke prevention Trial
Exercise capacity ; peak oxygen consumption ;VO2 ; ml/kg/min ; QOL ; Minnesota Living with Heart Failure ; mlHF
TAC-induced proteomic alterations ; mitochondrial-targeted peptide SS31 ; perturbed mitochondrial function ; pathway alterations ; TAC ; mitochondrial-targeted peptide drugs ; treatment heart failure
ventricular ejection fraction ; patients ; HF ; ventricular ejection fraction ; hospital ; physicians busy ; acute ; outpatient
hf ; left ventricular ;LV ; ejection fraction ; hpEF ; echo-Doppler studies ; pro-brain-type natriuretic peptide
low-volume EDs
cardiac transplant ; ECCT patients ; diabetes mellitus ; chronic kidney disease ; glomerular filtration
hABC Battery scores ; Health ABC HF Risk Model ; discrimination ; c-index ;net-reclassification-improvement
cf ; RMsea ; Self-Care Maintenance Scale ; cFI ; msea ; Self-Care management Scale ; cFI ; msea ; self-Care Confidence scale
BAT ; distance walked ; quality-of-life score
preoperative hypoalbuminemia ; postoperative normalization ; albumin levels ; hypoalbuminemia ; lVAD
rehospitalization ; acute myocardial infarction ; am ; complications ; kidney infection ; urinary tract infection ;UTI
heart failure ; ischemic ; nonischemic cardiomyopathies ; pharmacological armamentarium ; implantable cardioverter defibrillators ; cardiac resynchronization therapy ; cardiac transplantation ; ventricular assist devices
SAF ; PF ; figure ; central venous pressure ; hg ; hg ; sVR index ; figure
admission median bNP ; figure ; EF ; bp ; bp ; figure
heart failure admission ; heart transplantation ;LV assist device ; death ;hazard ratio
ejection fraction ; vitesse ; circumferential shortening ; systolic elastance ; contractile efficiency ; aCF ; allopurinol rats ; o2 consumption rate ; cardiomyocytes ; extracellular flux analyzer
HFpEF ; LV structure ; normal geometry ; LV hypertrophy ; mlh ; relative wall thickness ;RWt ; CR ; LVh ; RWT ; hz
angiotensin receptor neprilysin inhibitor ; neprilysin inhibitor prodrug ; angiotensin receptor antagonist valsartan ; hypertension ; pilot trial of heart failure ; preserved ejection fraction
blood pressure ; mitral valve plasty ; degenerative MR ; chordal ruptures ; triangular resection ; edge-to-edge anastomosis ; ring annuloplasty ; Physio Ring ; edwards Lifesciences ; irvine
shuttle walk test ; oxygen uptake ; muscular strength ; echocardiographic measures ; pro-brain natriuretic peptide ; inflammatory markers ; depression ; beck depression inventory
risk ; LVEF ; long-term mortality
grestar-Kyoto ; lean ZSF ; obese ZSF1 ; obese ZSF1 ; high-fat diet ; metabolic ; renal ; echocardiographic evaluations ; hemodynamically
Kaplan-Meier curves ; log-rank testing ; risk stratification
multivariate cox regression ; AF type ; long-standing persistent AF ; hypertension ; maintenance of sinus rhythm ;hazard ratio
chronic HF-ref ; NYHA functional class II ; eGFR ; potassium ; eplerenone ; hyperkalemia ; wRF
Ff ; FM ; body fat distribution ; dual energy X-ray absorptiometry ; dXA ; non-diabetic patients ; chronic heart failure ;CHf ;cc ; CHF ; myocardial infarction-both
drug dose ; spironolactone ; end point of death ; hospitalization ; HF ; AAs
pulmonary arterial hypertension ; inoperable chronic thromboembolic pulmonary hypertension ; impaired right ventricular pump ; pulmonary arterial hypertension medication ; stress echocardiography ; cardiopulmonary exercise
cardiovascular death ; HF hospitalization ; btes ; btes ; cardiovascular death ; HF
index ED visit ; low-volume ED cases ; 30-day death/all-cause readmission
implantable cardioverter-defibrillator deactivation ; implantable cardioverter-defibrillator deactivation
Cardiac magnetic resonance ; left atrial area ; pulmonary vascular resistance
HF units ; systolic ; left ventricular ejection fraction ; HF ; New York Heart Association class ; echocardiographic ; cardiopulmonary exercise
heart failure ; ABCd classification ; American College of Cardiology ; acc ;American Heart Association ; AHA ; New York Heart Association ;NYHA ; structural heart disease ; heart failure
mva ; continuity equation ; mlva ; mlva ; mlva ; mlva ; mlva ; mlva ; mitral filling flow ; mlva ; mitral filling flow ; continuous wave doppler echocardiography ; MR
statitistical significance ; RM ; all-cause mortality ; sts ; h ; ms ; office hours
HFPSI ; Ann Arbor Veterans Affairs HF clinic ;VA-RT cohort ; HFPSI ; VA patients ; HFPSI ; HFPSI
AAs ; spironolactone dose ; hyperkalemia ; potassium
long-term mortality ; LVEF ;hazard ratio
HFpEF ; HFpEF ; figure ; NYha class III ; distance covered ; mwt ; adherence ; medications
pulmonary arterial systolic pressure ;PASp ; right ventricular ; RV ; annular plane systolic excursion ;TAPSe ; diastole ; end-systole ; clinical follow-up of heart failure ;HF
diabetes ; electrocardiographic Q waves ; left bundle branch block ; nondiabetes risk factors ; dyslipidemia ; hypertension ; tobacco
receiver operating characteristic curve ; auc ; ratios ; PCWP
trastuzumab-treated patients ; coronary artery disease ; h ; hypertension ; h ; CHF
LVEF ; clinical composite response ; cRT ON ; cRT OFF ; LV end systolic volume index
tGF-β signaling ; tGF-β receptor ; smad ; small-molecule inhibitors ; c-Kit ; cell yield ; epithelial ; mesenchymal transition markers ; pluripotency marker nanog ; c-Kit ; cell differentiation ; cardiomyocyte-like cells in vitro
hfrf ; diuretics ; co-morbidities ; mwt ; NYHA class III
surgery ; HF ; postoperative echocardiography ; LV ; end-diastolic volume index ; ml ; LV ejection fraction ; MR ; mitral valve opening ; mva ; pression gradient ; hg
systolic heart failure ; ivabradine ; SHIFT ; Systolic Heart Failure Treatment ; If inhibitor ivabradine Trial ; ivabradine ; echocardiographic substudy
multivariate regression ; tAPse/PASp ; hg ; hg ; hz ; hz ; hz ; hz ; hz ; hz
Chronic Kidney Disease Epidemiology Collaboration equation ; glomerular filtration rate ; eGFR
multicenter trial PARADIGm-HF ; chronic heart failure ; systolic dysfunction ;LV ; functional class NYHA II-III ; bNP ; bNP ;cardiovascular death ; hospitalization for heart failure ; ARNI ; sacubiltril ; valsartan
reverse remodeling ; pre-CRT LV ; end-diastolic dimension ; global longitudinal strain ; left ventricle ; left atrial area ; ventricular end-diastolic area ; right atrial ; ventricular fractional area change
hyperkalemia ; African Americans ; AAs ; non-AAs ; white ; heart association ;NYHA ; HF ; left ventricular dysfunction ; spironolactone ; aldactone Evaluation Study ;RALes
iRS1 ; iRS2 ; hyperinsulinemia ; myocardial insulin resistance ; cellular dysfunction ; iRS2 ; heart-specific iRS1 ; iRS2 double-knockout ; h-dKO ; liver-specific iRS1 ; iRS2 double-knockout ; l-dKO
natriuretic peptide ; n-terminal pro-B-type natriuretic peptide ; stable coronary artery disease ; bNP ; ventricular cardiomyocytes ; ventricular wall stress ; myocardial ischemia
angiotensin-converting enzyme inhibitors ;angiotensin receptor blockers ; interquartile
ivabradine ; therapy ; ivabradine
liberal transfusion protocols ; short-term mortality rates ; aggressive protocols
risk of death ; unplanned readmission
hEK ; embryonic kidney ; cells ; β1AR ; s1PR1 downregulation ; sphingosine-1-phosphate ; agonist ; isoproterenol ; β-adrenergic receptor agonist
Kansas City Cardiomyopathy Questionnaire ; Minnesota Living with Heart Failure Questionnaire ; depressive symptoms ; beck depression inventory ; depression ; natriuretic peptide ; endothelial function ;flow-mediated dilatation ; ventricular diastolic
cardiovascular events ; atrial fibrillation ; left ventricular ejection fraction ; diabetes mellitus ; peripheral vascular disease ; myocardial infarction ; heart failure ; stroke
conjunction ; diastolic function ; ventricular-arterial coupling
disease risk score ; dRS ; sitagliptin ; saxagliptin ; pioglitazone ; saxagliptin ; sulfonylureas ; insulin
revascularization ; coronary artery bypass surgery ; hazard ratio ; percutaneous coronary intervention ; h ; systolic blood pressure ; left bundle branch block pattern ; baseline electrocardiogram
biomedical treatment ; biomedical treatment ; CHm ; ventricular ejection fraction ; figure ; left ventricular diastolic end diameter
open-label crossover study ; stable heart failure patients ; left ventricular ejection fraction ; figure ; β2-receptor ; carvedilol ; metoprolol
low-volume ED cases ; death/hospitalization/ED
health Buddy Program ; risk-adjusted all-cause mortality ;hazard ratio ;HR ; confidence interval ; CI
multivariable-adjusted hazard ratios
ctt ; NT-probNP ; aRIC HF ; systolic blood pressure ; antihypertensive medication ; smoking ; diabetes ; coronary heart disease ; heart rate ; HF ; receiver operating characteristic curve ; discrimination improvement ; net reclassification improvement ; nRI
eplerenone ; hyperkalemia ; renal function ; wRF ; EMPHASIS-HF ; heart failure ; reduced ejection fraction ; h-ref ; New York Heart Association ;NYHA ; glomerular filtration rate ; eGFR ; serum potassium
low-dose nesiritide ; 72-hour cumulative urine volume ;nesiritide ; ml ; figure ; cystatin C
Nordic walking ; functional capacity ; m ; m ; m ; mwt ; physique activity ; depressive symptoms ; hospital anxiety and depression
hyperkalemia ; wRF ; diabetes ; egFR ; systolic blood pressure ; hg ; hyperkalemia ;drug discontinuation ; hospitalization ; wRF ;hospitalization ; HF ; cardiovascular mortality
PAf ; biosynthetic enzymes ;lyso-paf acetyltransferase ;lyso-paf-AT ; dithiothreitol ; dt ; CDp choline ; 1-alkyl-2-acetyl-sn-glycerol cholinephosphotransferase ; pf-cPT ; catabolic isoenzymes ;PAf-acetylhydrolase ; pf-AH ; lipoprotein-associated phospholipase ; lp-PLA
ivabradine group ; baseline ; follow-up exercise capacity ; METs ; peak oxygen uptake
CHF ; ht chest radiation ; hypertension ; genes coding ; NAD ; h-oxidase subunit RAC2 ; hf ; doxorubicin efflux transporter ABCc2
NYHA classification ; class III ; class II ; figure ; Duke Activity Status Index ; Kansas City Cardiomyopathy
low-dose dopamine ; 72-hour cumulative urine volume ;dopamine ; figure ; cystatin C
hard ratio ; figure ; baseline glomerular filtration rate ; h ; figure ; chronic obstructive pulmonary disease ; diabetes ; h ; ventricular ejection fraction ; h ; inappropriate iCD shocks ; New York Heart Association class ; atrial fibrillation ; congestive HF
peak oxygen uptake ; hazard ratio ; confidence interval ; ventilatory efficiency slope ; hemoglobin ; ventricular ejection fraction ; renal disease ; sodium
Kansas City Cardiomyopathy Questionnaire ; Minnesota Living with Heart Failure Questionnaire ; Beck depression inventory ; zung ; flow-mediated dilatation diameter ; fes ; placebo ; b-type natriuretic peptide
